var title_f42_14_43232="Applying stockings A";
var content_f42_14_43232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Putting on compression stockings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43232=[""].join("\n");
var outline_f42_14_43232=null;
var title_f42_14_43233="One-legged hyperextension";
var content_f42_14_43233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    One-legged hyperextension test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The test is performed by having the patient hyperextend his or her lumbar spine while standing on a single leg. This test is used in the evaluation of a suspected spondylolytic defect at the pars interarticularis. The test is positive if the patient's pain is reproduced. A positive test may indicate an active spondylolysis and/or irritation of the facet structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43233=[""].join("\n");
var outline_f42_14_43233=null;
var title_f42_14_43234="Normal abdominal aorta";
var content_f42_14_43234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal abdominal aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The abdominal aorta is a retroperitoneal structure that begins at the hiatus of the diaphragm and extends to its bifurcation into the right and left common iliac arteries at the level of the fourth lumbar vertebra.",
"    <br>",
"     The branches of the abdominal aorta include (superior to inferior) the left and right inferior phrenic arteries, the celiac axis, left and right middle suprarenal arteries, superior mesenteric artery, left and right renal arteries, left and right gonadal arteries, inferior mesenteric artery, left and right common iliac artery, and middle sacral artery. The paired lumbar arteries (L1-L4) branch from the aorta at mid vertebral body.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43234=[""].join("\n");
var outline_f42_14_43234=null;
var title_f42_14_43235="Eventration of the diaphragm in infants";
var content_f42_14_43235=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eventration of the diaphragm in infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43235/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/14/43235/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eventration of the diaphragm is a disorder in which all or part of the diaphragmatic muscle is replaced by fibroelastic tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The diaphragm retains its continuity and attachments to the costal margin. However, the weakened hemidiaphragm is displaced into the thorax, which can compromise breathing. With diaphragmatic hernia, in contrast, this continuity between the diaphragm and the costal margin is disrupted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of eventration is uncertain, although in one report, the condition was detected in 1 per 1400 patients who had chest radiographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/3\">",
"     3",
"    </a>",
"    ]. More males than females are affected. Congenital eventrations can be isolated, although they sometimes are associated with other developmental defects such as cleft palate, congenital heart disease, situs inversus, or undescended testicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eventration of the diaphragm can be congenital or acquired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Congenital eventration results from inadequate development of the muscle or absence of the phrenic nerves. The most common cause of acquired eventration is injury to the phrenic nerve, resulting from either a traumatic birth or thoracic surgery for congenital heart disease. The loss of contractility leads to muscle atrophy with elevation of the hemidiaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36951?source=see_link\">",
"     \"Diaphragmatic paralysis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The defect in congenital eventration can be partial or diffuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. In the former, the defect is localized; whereas, in the latter, the diaphragm consists of a thin, diaphanous membrane that is attached peripherally to normal muscle. In one series, partial defects, mostly affecting the right hemidiaphragm, occurred in 65 percent of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/8\">",
"     8",
"    </a>",
"    ]. Diffuse defects also tend to be unilateral but occur more commonly on the left side.",
"   </p>",
"   <p>",
"    In the acquired form, the central tendon is normal and the diaphragm consists of normally developed muscle that is atrophic. The phrenic nerve typically is small. Both sides are affected equally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients are asymptomatic, especially when the eventration is localized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/5\">",
"     5",
"    </a>",
"    ]. However, large defects in newborns can cause respiratory distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/9\">",
"     9",
"    </a>",
"    ]. The degree of respiratory distress can be increased by factors other than the size of the defect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some children have lung hypoplasia on the affected side [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/10\">",
"       10",
"      </a>",
"      ]. In addition, if the mediastinum is shifted, hypoplasia also can occur on the contralateral side.",
"     </li>",
"     <li>",
"      Compression of the lung bases can cause atelectasis and poor drainage and can lead to the development of bronchopneumonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although respiratory signs are most common, some patients develop gastrointestinal abnormalities. They include feeding difficulty, nausea, vomiting, or indigestion. Gastrointestinal findings are related to rotation of the gastric fundus and sometimes the bowel into the elevated diaphragm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of eventration is suspected in infants with respiratory distress or when a hemidiaphragm appears elevated on a frontal or lateral chest radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51466 \" href=\"mobipreview.htm?41/35/42559\">",
"     image 1",
"    </a>",
"    ). Other radiographic findings that may be seen include shift of the mediastinum, atelectasis, and elevation of the stomach.",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by fluoroscopy or ultrasonography. Diaphragm movement during breathing typically is minimal or is paradoxical, rising with inspiration and falling with expiration. If surgery is required, the atrophied muscle in the eventrated area can be visualized directly.",
"   </p>",
"   <p>",
"    Elevation of the hemidiaphragm also occurs in infants with diaphragmatic paralysis. Most of these patients have a history of birth trauma with brachial plexus injury, although phrenic nerve injury can be isolated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36951?source=see_link\">",
"     \"Diaphragmatic paralysis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of eventration depends upon the extent of respiratory distress. If respiratory distress is mild, the management is supportive. Support may include supplemental oxygen administered by hood or nasal cannula. If oral feedings are limited because of respiratory distress, nasogastric feedings are used to provide adequate calories. Nasogastric feeds are discontinued gradually as the infant begins to take sufficient bottle or breast feeding for growth. Parenteral nutrition may be needed initially to supplement enteral feeding until weight gain is established.",
"   </p>",
"   <p>",
"    If patients have persistent severe respiratory distress or require mechanical ventilation, surgical plication is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. This procedure immobilizes and lowers the diaphragm, resulting in increased resting lung volume and improved action of the intercostal and abdominal muscles during breathing. Respiratory improvement after application of continuous positive airway pressure (8 to 10 cmH2O) may identify patients who will respond to plication because both interventions stabilize the diaphragm and increase functional residual capacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Video-assisted thoracic surgery may offer a less invasive approach because it avoids the incision of the lower intercostal muscles, which may adversely affect ventilation. Although most of the clinical experience with this intervention is in adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/14\">",
"     14",
"    </a>",
"    ], video-assisted thoracic surgery was performed successfully in newborn infants with birth weights as low as 2.2 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. There are more reports utilizing minimally invasive surgery using either thoracoscopy or laparoscopy for the repair of diaphragmatic abnormalities in newborn infants with weight ranges of 2.2 to 22 kilograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/16\">",
"     16",
"    </a>",
"    ]. This procedure could potentially reduce postoperative recovery and morbidity in infants with congenital eventration.",
"   </p>",
"   <p>",
"    The appropriate timing for surgical correction is uncertain. In one report, early surgical intervention resulted in reduced respiratory rate and improved weight gain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/6\">",
"     6",
"    </a>",
"    ]. Performing early surgery may prevent the progression of pathological changes in the lung. In a report that included both congenital and acquired eventration, lung biopsies at the time of surgery (10 days to 6 years) showed that atelectasis and pneumonia increased in extent and severity with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on outcomes after diaphragm plication are limited. In one report from Turkey, 12 patients with congenital eventration were evaluated 1.5 to 11 years after surgery that was performed before the patients reached four years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/12\">",
"     12",
"    </a>",
"    ]. Satisfactory motion of the diaphragm was observed with fluoroscopy in nine of the patients, and measurements of muscle thickness showed that growth of the plicated and contralateral sides was similar. Pulmonary function tests were normal in five of the six patients who could be tested. In another report, plication did not appear to impede return of diaphragm function in patients with acquired defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43235/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eventration of the diaphragm occurs when all or part of the diaphragmatic muscle is replaced by fibroelastic tissue. In this condition, although the diaphragm retains its continuity and attachments to the costal margin, the weakened hemidiaphragm is displaced into the thorax, which can compromise breathing. Diaphragmatic hernia, in contrast, involves a disruption of this continuity between the diaphragm and the costal margin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eventration of the diaphragm can be either congenital or acquired. Congenital eventration can be isolated or be associated with other anomalies. The most common cause of acquired eventration is due to phrenic nerve injury resulting from traumatic birth or surgery for congenital heart disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory distress is the most common clinical manifestation. However, findings vary depending upon the size of the defect. In some cases of small localized eventration, patients are asymptomatic, whereas large defects in newborn infants can cause respiratory distress. Other factors associated with diaphragmatic eventration that increase respiratory distress include lung hypoplasia, atelectasis, and bronchopneumonia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal findings due to rotation of the gastric fundus and the bowel into the elevated diaphragm include feeding difficulty, nausea, vomiting, or indigestion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of eventration is suspected when a hemidiaphragm appears elevated on chest radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51466 \" href=\"mobipreview.htm?41/35/42559\">",
"       image 1",
"      </a>",
"      ) and is confirmed by fluoroscopic or ultrasonic demonstration of minimal or paradoxical diaphragmatic movement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy depends upon the size of the defect. In patients with mild respiratory distress, management is supportive and includes supplemental oxygen, and nasogastric feedings or parental nutrition as symptoms generally resolve with growth. If patients have persistent or severe disease, surgical plication is usually required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/1\">",
"      BISGARD JD. Congenital eventration of the diaphragm. J Thorac Surg 1947; 16:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/2\">",
"      Shah-Mirany J, Schmitz GL, Watson RR. Eventration of the diaphragm. Physiologic and surgical significance. Arch Surg 1968; 96:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/3\">",
"      CHIN EF, LYNN RB. Surgery of eventration of the diaphragm. J Thorac Surg 1956; 32:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/4\">",
"      Smith CD, Sade RM, Crawford FA, Othersen HB. Diaphragmatic paralysis and eventration in infants. J Thorac Cardiovasc Surg 1986; 91:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/5\">",
"      Deslauriers J. Eventration of the diaphragm. Chest Surg Clin N Am 1998; 8:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/6\">",
"      Obara H, Hoshina H, Iwai S, et al. Eventration of the diaphragm in infants and children. Acta Paediatr Scand 1987; 76:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/7\">",
"      Reed, JA, Borden, DL. Eventration of the diaphragm. Arch Surg 1935; 31:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/8\">",
"      Wayne ER, Campbell JB, Burrington JD, Davis WS. Eventration of the diaphragm. J Pediatr Surg 1974; 9:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/9\">",
"      Thomas TV. Congenital eventration of the diaphragm. Ann Thorac Surg 1970; 10:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/10\">",
"      Goldstein JD, Reid LM. Pulmonary hypoplasia resulting from phrenic nerve agenesis and diaphragmatic amyoplasia. J Pediatr 1980; 97:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/11\">",
"      Par&iacute;s F, Blasco E, Cant&oacute; A, et al. Diaphragmatic eventration in infants. Thorax 1973; 28:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/12\">",
"      Kizilcan F, Tanyel FC, Hi&ccedil;s&ouml;nmez A, B&uuml;y&uuml;kpamuk&ccedil;u N. The long-term results of diaphragmatic plication. J Pediatr Surg 1993; 28:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/13\">",
"      Haller JA Jr, Pickard LR, Tepas JJ, et al. Management of diaphragmatic paralysis in infants with special emphasis on selection of patients for operative plication. J Pediatr Surg 1979; 14:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/14\">",
"      Mouroux J, Venissac N, Leo F, et al. Surgical treatment of diaphragmatic eventration using video-assisted thoracic surgery: a prospective study. Ann Thorac Surg 2005; 79:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/15\">",
"      Shimizu M. Bilateral phrenic-nerve paralysis treated by thoracoscopic diaphragmatic plication in a neonate. Pediatr Surg Int 2003; 19:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/16\">",
"      Shah SR, Wishnew J, Barsness K, et al. Minimally invasive congenital diaphragmatic hernia repair: a 7-year review of one institution's experience. Surg Endosc 2009; 23:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43235/abstract/17\">",
"      Schwartz MZ, Filler RM. Plication of the diaphragm for symptomatic phrenic nerve paralysis. J Pediatr Surg 1978; 13:259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5054 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43235=[""].join("\n");
var outline_f42_14_43235=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5054\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5054|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/35/42559\" title=\"diagnostic image 1\">",
"      Elevated right hemidiaphragm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/5/36951?source=related_link\">",
"      Diaphragmatic paralysis in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_14_43236="Terazosin: Pediatric drug information";
var content_f42_14_43236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terazosin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"    see \"Terazosin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33268?source=see_link\">",
"    see \"Terazosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Terazosin&reg;;",
"     </li>",
"     <li>",
"      Dom-Terazosin;",
"     </li>",
"     <li>",
"      Hytrin&reg;;",
"     </li>",
"     <li>",
"      Nu-Terazosin;",
"     </li>",
"     <li>",
"      PHL-Terazosin;",
"     </li>",
"     <li>",
"      PMS-Terazosin;",
"     </li>",
"     <li>",
"      ratio-Terazosin;",
"     </li>",
"     <li>",
"      Teva-Terazosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1037955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1037984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=see_link\">",
"      see \"Terazosin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     If drug is discontinued for greater than several days, consider beginning with initial dose and retitrate as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1 mg once daily typically administered at bedtime; slowly increase dose to achieve desired blood pressure as tolerated; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Benign prostatic hyperplasia:",
"     </b>",
"     Oral: Initial: 1 mg at bedtime; thereafter, titrate upwards, if needed, over several weeks, balancing therapeutic benefit with terazosin-induced postural hypotension; most patients require 10 mg day; if no response after 4-6 weeks of 10 mg/day, may increase to 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1 mg at bedtime; slowly increase dose to achieve desired blood pressure, up to 20 mg/day; usual dose range (JNC 7): 1-20 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage may be given on a twice-daily regimen if response is diminished at 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1 mg, 2 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14787709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to meals at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F14787703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light and moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1037956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of benign prostate hyperplasia (BPH) (FDA approved in adults); treatment of hypertension alone or in combination with other agents, such as diuretics or beta-blockers (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14187919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F225543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, palpitation, peripheral edema, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, extremity pain, muscle weakness, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, abnormal vision, allergic reactions, anaphylaxis, anxiety, arrhythmia, arthralgia, arthritis, atrial fibrillation, bronchitis, chest pain, conjunctivitis, constipation, cough, diaphoresis, diarrhea, dyspepsia, epistaxis, facial edema, fever, flatulence, flu-like syndrome, gout, insomnia, intraoperative floppy iris syndrome (IFIS), joint disorder, myalgia, neck pain, pharyngitis, polyuria, priapism, pruritus, rash, rhinitis, shoulder pain, thrombocytopenia, tinnitus, urinary incontinence, urinary tract infection, vasodilation, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1037959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to terazosin, quinazolines (prazosin, doxazosin), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F14787699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Use with caution in patient with cataracts or undergoing corrective cataract surgery; intraoperative floppy iris syndrome (IFIS) has been observed in cataract surgery patients receiving or who were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; there appears to be no benefit in discontinuing alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers prior to surgery.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1037960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Marked orthostatic hypotension, syncope, and loss of consciousness may occur with first dose or first few days of therapy; syncope usually occurs 30-90 minutes after initial dose; occasionally preceded with severe supraventricular tachycardia (120-160 bpm in adults); anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, if large initial dose (&ge;2 mg in adults), or if another antihypertensive drug (eg, beta-blockers, diuretics, and particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy, after an interruption of therapy, or when adjusting dosage upward. May cause priapism (rarely).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1037973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food delays time to reach peak serum concentration by ~40 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8119801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal studies. Decreased fetal weight and increased risk of fetal mortality were noted in some animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1037988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Standing and sitting/supine blood pressure, especially 2-3 hours after the initial dose, then prior to doses (to ensure adequate control throughout the dosing interval); urinary symptoms if used for BPH treatment",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1037974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypertension: Competitively inhibits postsynaptic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BPH: Competitively inhibits postsynaptic alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors in prostatic stromal and bladder neck tissues. This reduces the sympathetic tone-induced urethral stricture causing BPH symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F14787704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Antihypertensive effect: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: Antihypertensive effect: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Antihypertensive effect: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1037976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid, complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; minimal first pass",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (~60%, ~20% as unchanged drug); urine (~40%, ~10% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: ~10% removed during hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1037991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33268?source=see_link\">",
"      see \"Terazosin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take consistently with regard to meals. Avoid alcohol; rise slowly from sitting or lying position; may cause dizziness or drowsiness, headache, or nausea; ability to perform activities requiring mental alertness or physical coordination may be impaired; may cause dry mouth. Report increased nervousness or depression, sudden weight gain, palpitations or rapid heartbeat, muscle weakness, fatigue, vision changes, rash, or changes in urinary pattern.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43236/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86243 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43236=[""].join("\n");
var outline_f42_14_43236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225499\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037955\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037984\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225478\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225464\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787709\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787703\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037956\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14187919\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225543\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037959\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787699\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037960\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300112\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225473\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037973\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225474\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119801\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037988\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037974\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14787704\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037976\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1037991\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86243\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/86243|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/15/36085?source=related_link\">",
"      Terazosin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/31/33268?source=related_link\">",
"      Terazosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_14_43237="Developmental pathogenesis osteomyelitis";
var content_f42_14_43237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Developmental pathogenesis of acute osteomyelitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 624px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) In newborns, infection spreads along the subperiosteal space and ruptures through cortex, into soft tissue. Infection spreads to the epiphysis and joint space through metaphyseal capillaries that cross the physis. B, C) In infants and older children, capillaries do not cross the physis. Infection is confined to the metaphysis. Thicker cortex and denser periosteum prevent spread to soft tissues and localize infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43237=[""].join("\n");
var outline_f42_14_43237=null;
var title_f42_14_43238="Colistin (colistimethate): Drug information";
var content_f42_14_43238=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Colistin (colistimethate): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/11/22708?source=see_link\">",
"    see \"Colistin (colistimethate): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/10/32933?source=see_link\">",
"    see \"Colistin (colistimethate): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coly-Mycin&reg; M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Coly-Mycin&reg; M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be based on ideal body weight in obese patients; dosage expressed in terms of",
"     <b>",
"      colistin base",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 2.5-5 mg/kg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation (unlabeled use): 50-75 mg in NS (3-4 mL total) via nebulizer 2-3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningitis (susceptible gram-negative organisms):",
"     </b>",
"     Intrathecal/Intraventricular (unlabeled route): 10 mg/day (IDSA, 2004);",
"     <b>",
"      Note:",
"     </b>",
"     Dosage in clinical reports has ranged from 1.6-20 mg/day in 1 or 2 divided doses (maximum single dose: 10 mg)  (administered with concomitant systemic antimicrobial therapy) (Guardado, 2008; Kasiakou, 2005; Katragkou, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis (unlabeled dose):",
"     </b>",
"     I.V.: 3 mg/kg/day in 3 divided doses (Young, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ventilator-associated pneumonia due to multidrug-resistant",
"      <b>",
"       <i>",
"        Pseudomonas aeruginosa",
"       </i>",
"      </b>",
"      or",
"      <b>",
"       <i>",
"        Acinetobacter baumannii",
"       </i>",
"      </b>",
"      (unlabeled use):",
"     </b>",
"     Nebulization (via ventilator circuit): 150 mg every 8 hours delivered over 60 minutes for 14 days or until successful wean from mechanical ventilation (treatment duration range: 7-19 days) (Lu, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/10/32933?source=see_link\">",
"      see \"Colistin (colistimethate): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be based on ideal body weight in obese patients; dosage expressed in terms of",
"     <b>",
"      colistin base",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Susceptible infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: 2.5-5 mg/kg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation (unlabeled use): 50-75 mg in NS (3-4 mL total) via nebulizer 2-3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cystic fibrosis (unlabeled dose):",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F154563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be based on ideal body weight in obese patients; dosage expressed in terms of",
"     <b>",
"      colistin base",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.3-1.5 mg/dL: ~2.5-3.8 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     1.6-2.5 mg/dL: ~2.5 mg/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     2.6-4 mg/dL: ~1.5 mg/kg every 36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): 1.5 mg/kg every 24-48 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH/CVVHD/CVVHDF: 2.5 mg/kg every 24-48 hours (frequency dependent upon site or severity of infection or susceptibility of pathogen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A single case report has demonstrated that the use of 2.5 mg/kg every 48 hours with a dialysate flow rate of 1 L/hour may be inadequate and that dosing every 24 hours was well-tolerated. Based on pharmacokinetic analysis, the authors recommend dosing as frequent as every 12 hours in patients receiving CVVHDF (Li, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [strength expressed as base]: colistin 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coly-Mycin&reg; M: colistin 150 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer by I.M., direct I.V. injection over 3-10 minutes, intermittent infusion over 30 minutes, or by continuous I.V. infusion. For continuous I.V. infusion, one-half of the total daily dose is administered by direct I.V. injection over 3-10 minutes followed 1-2 hours later by the remaining one-half of the total daily dose diluted in a compatible I.V. solution infused over 22-23 hours. The final concentration for administration should be based on the patient's fluid needs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation (unlabeled route): Administer solution via nebulizer promptly following preparation to decrease possibility of high concentrations of colistin from forming which may lead to potentially life-threatening lung toxicity. Consider use of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le, 2010). If patient is on a ventilator, place medicine in a T-piece at the midinspiratory circuit of the ventilator. One study in adult patients with VAP administered colistimethate (150 mg colistin base /10 mL SWFI) over 60 minutes (Lu, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal/intraventricular (unlabeled route): Administer only preservative-free solutions via intrathecal/intraventricular routes. Administer promptly after preparation. Discard unused portion of vial.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F154578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Variable (consult detailed reference):",
"     </b>",
"     Telavancin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, cloxacillin, penicillin G sodium.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections due to sensitive strains of certain gram-negative bacilli which are resistant to other antibacterials or in patients allergic to other antibacterials",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F154570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used as nebulized inhalation in the prevention of",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     respiratory tract infections in immunocompromised patients; used as nebulized inhalation adjunct agent for the treatment of",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     infections in patients with cystic fibrosis and other seriously ill or chronically ill patients; used as nebulized inhalation in the treatment of ventilator-associated pneumonia (VAP) due to multidrug-resistant",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     or",
"     <i>",
"      A. baumannii",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14219656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Due to the potential for dosing errors, it is recommended that prescriptions for colistimethate be expressed as colistin base only.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, slurred speech, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (extremities, oral); weakness (lower limb)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, nephrotoxicity, proteinuria, urine output decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, respiratory arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing, and/or case reports: Lung toxicity (bronchoconstriction, bronchospasm, chest tightness, respiratory distress, acute respiratory failure following inhalation)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to colistimethate, colistin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchoconstriction: Use of inhaled colistimethate (unlabeled route) may result in bronchoconstriction. Use with caution in patients with hyperactive airways; consider administration of a bronchodilator (eg, albuterol) within 15 minutes prior to administration (Le, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Transient, reversible neurological disturbances (eg, dizziness, numbness, paresthesia, tingling, vertigo) may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal toxicity: Dose-dependent nephrotoxicity has been reported, generally reversible upon discontinuation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Respiratory arrest has been reported with use; impaired renal function may increase the risk for neuromuscular blockade and apnea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal disease; dosage adjustments may be required. Impaired renal function may increase the risk for respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Inhalation (unlabeled route):  Once mixed, colistimethate begins conversion to bioactive colistin, a component of which may result in severe pulmonary toxicity (Le, 2010). Solutions for inhalation must be mixed immediately prior to administration and used within 24 hours to reduce the incidence of pulmonary toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Safety: Potential for dosing errors due to lack of standardization in literature when referring to product and dose; colistimethate (inactive prodrug) and colistin base strengths are not interchangeable; verify prescribed dose is expressed in terms of colistin base prior to dispensing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5105300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies colistimethate as pregnancy category C. Colistimethate crosses the placenta in humans. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5105302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5105303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if colistimethate sodium is excreted in human milk, but colistin sulphate (another form of colistin)  is excreted in human milk. The manufacturer recommends caution if giving colistimethate sodium to a breast-feeding woman. If colistimethate sodium reaches the breast milk, nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Colistimethate Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (1): $33.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Coly-Mycin M Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (1): $33.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5105494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum creatinine, BUN; urine output; signs of neurotoxicity; signs of bronchospasm (inhalation [unlabeled route])",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alficetin (AR);",
"     </li>",
"     <li>",
"      Colimicina IM (IT);",
"     </li>",
"     <li>",
"      Colimycin (CL, NO);",
"     </li>",
"     <li>",
"      Colimycine (FR);",
"     </li>",
"     <li>",
"      Coliracin (IL);",
"     </li>",
"     <li>",
"      Colistate (TH);",
"     </li>",
"     <li>",
"      Colistin (CH, NL);",
"     </li>",
"     <li>",
"      Colistin Link (AU, NZ);",
"     </li>",
"     <li>",
"      Colistineb (BE);",
"     </li>",
"     <li>",
"      Colixin (PT);",
"     </li>",
"     <li>",
"      Colomycin (CZ, HK, HN, IE);",
"     </li>",
"     <li>",
"      Costim (TW);",
"     </li>",
"     <li>",
"      Promixin (DE, DK, GB, IE);",
"     </li>",
"     <li>",
"      Tadim (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Colistimethate (or the sodium salt [colistimethate sodium]) is the inactive prodrug which is hydrolyzed to colistin, which acts as a cationic detergent which damages the bacterial cytoplasmic membrane causing leaking of intracellular substances and cell death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely, except for CNS, synovial, pleural, and pericardial fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Colistimethate sodium (inactive prodrug) is hydrolyzed to colistin (active form)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.M., I.V.: 2-3 hours; Anuria: &le;2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: I.V.: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alothman GA, Ho B, Alsaadi MM, et al, &ldquo;Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2005, 127(2):522-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/15705991/pubmed\" id=\"15705991\" target=\"_blank\">",
"        15705991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bauldoff GS, Nunley DR, Manzetti JD, et al, &ldquo;Use of Aerosolized Colistin in Cystic Fibrosis Patients Awaiting Lung Transplantation,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 1997, 64(5):748-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/9311714/pubmed\" id=\"9311714\" target=\"_blank\">",
"        9311714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beringer P, &ldquo;The Clinical Use of Colistin in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       Curr Opin Pulm Med",
"      </i>",
"      , 2001, 7(6):434-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/11706322/pubmed\" id=\"11706322\" target=\"_blank\">",
"        11706322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bosso JA, Liptak CA, Seilheimer DK, et al, &ldquo;Toxicity of Colistin in Cystic Fibrosis Patients,&rdquo;",
"      <i>",
"       DCIP",
"      </i>",
"      , 1991, 25(11):1168-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/1763528/pubmed\" id=\"1763528\" target=\"_blank\">",
"        1763528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quinn AL, Parada JP, Belmares J, et al, \"Intrathecal Colistin and Sterilization of Resistant",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      Shunt Infection,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(5):949-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/15811909/pubmed\" id=\"15811909\" target=\"_blank\">",
"        15811909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conway SP, Pond MN, Watson A, et al, &ldquo;Intravenous Colistin Sulphomethate in Acute Respiratory Exacerbations in Adult Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 1997, 52(11):987-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/9487348/pubmed\" id=\"9487348\" target=\"_blank\">",
"        9487348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guardado AR, Blanco A, Asensi V, et al, &ldquo;Multidrug-Resistant",
"      <i>",
"       Acinetobacter",
"      </i>",
"      Meningitis in Neurosurgical Patients With Intraventricular Catheters: Assessment of Different Treatments,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2008, 61(4):908-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/18281693/pubmed\" id=\"18281693\" target=\"_blank\">",
"        18281693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jensen T, Pederson SS, Garne S, et al, &ldquo;Colistin Inhalation Therapy in Cystic Fibrosis Patients With Chronic",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      Lung Infection,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1987, 19(6):831-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/3301785/pubmed\" id=\"3301785\" target=\"_blank\">",
"        3301785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kasiakou SK, Rafailidis PI, Liaropoulos K, et al, &ldquo;Cure of Post-Traumatic Recurrent Multiresistant Gram-Negative  Rod Meningitis With Intraventricular Colistin,&rdquo;",
"      <i>",
"       J Infect",
"      </i>",
"      , 2005, 50(4):348-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/15845435/pubmed\" id=\"15845435\" target=\"_blank\">",
"        15845435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katragkou A and Roilides E, &ldquo;Successful Treatment of Multidrug-Resistant",
"      <i>",
"       Acinetobacter baumannii",
"      </i>",
"      Central Nervous System Infections With Colistin,&rdquo;",
"      <i>",
"       J Clin Microbiol",
"      </i>",
"      , 2005, 43(9):4916-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/16145177/pubmed\" id=\"16145177\" target=\"_blank\">",
"        16145177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le J, Ashley ED, Neuhauser MM, et al, &ldquo;Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(6):562-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/20500046/pubmed\" id=\"20500046\" target=\"_blank\">",
"        20500046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li J, Rayner CR, Nation RL, et al, &ldquo;Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2005, 49(11):4814-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/16251342/pubmed\" id=\"16251342\" target=\"_blank\">",
"        16251342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lim LM, Ly N, Anderson D, et al, &ldquo;Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(12):1279-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/21114395/pubmed\" id=\"21114395\" target=\"_blank\">",
"        21114395",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lu Q, Luo R, Bodin L, et al, &ldquo;Efficacy of High-Dose Nebulized Colistin In Ventilator-Associated Pneumonia Caused By Multidrug-Resistant",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      and",
"      <i>",
"       Acinetobacter baumannii",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2012, 117(6):1335-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/23132092/pubmed\" id=\"23132092\" target=\"_blank\">",
"        23132092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCoy KS, &ldquo;Compounded Colistimethate as Possible Cause of Fatal Acute Respiratory Distress Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(22):2310-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/18046039/pubmed\" id=\"18046039\" target=\"_blank\">",
"        18046039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quinn AL, Parada JP, Belmares J, et al, &ldquo;Intrathecal Colistin and Sterilization of Resistant",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      Shunt Infection,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(5):949-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/15811909/pubmed\" id=\"15811909\" target=\"_blank\">",
"        15811909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed MD, Stern RC, O'Riordan MA, et al, &ldquo;The Pharmacokinetics of Colistin in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41(6):645-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/11402633/pubmed\" id=\"11402633\" target=\"_blank\">",
"        11402633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabuda DM, Laupland K, Pitout J, et al, &ldquo;Utilization of Colistin for Treatment of Multidrug-Resistant",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Can J Infect Dis Med Microbiol",
"      </i>",
"      , 2008, 19(6):413-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/19436571/pubmed\" id=\"19436571\" target=\"_blank\">",
"        19436571",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallace SJ, Li J, Rayner CR, et al, &ldquo;Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to Patients,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2008, 52(9):3047-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/18606838/pubmed\" id=\"18606838\" target=\"_blank\">",
"        18606838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young D, Zobell J, Waters C, et al, &ldquo;Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: IV. Colistimethate Sodium,&rdquo;",
"      <i>",
"       Ped Pulmonol",
"      </i>",
"      , 2013, 48(1):1-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/22949160/pubmed\" id=\"22949160\" target=\"_blank\">",
"        22949160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zylberberg H, Vargaftig J, Barbieux C, et al, &ldquo;Prolonged Efficiency of Secondary Prophylaxis With Colistin Aerosols for Respiratory Infection Due to",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      in Patients Infected With Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 23(3):641-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/14/43238/abstract-text/8879797/pubmed\" id=\"8879797\" target=\"_blank\">",
"        8879797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8718 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43238=[""].join("\n");
var outline_f42_14_43238=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154558\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154559\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154573\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154561\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154569\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154562\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154563\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795898\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154544\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154532\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154546\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154578\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154545\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154570\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14219656\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154571\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154549\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154536\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299084\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154540\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154542\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5105300\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5105302\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5105303\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323078\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5105494\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038587\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154535\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154548\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/11/22708?source=related_link\">",
"      Colistin (colistimethate): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/10/32933?source=related_link\">",
"      Colistin (colistimethate): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_14_43239="Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention";
var content_f42_14_43239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Lawrence Kim, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Anne T Mancino, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43239/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/14/43239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H32537546\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The repair of an abdominal wall hernia, which includes inguinal, ventral, incisional, femoral, umbilical, and paraumbilical hernias, is a generally clean procedure with a low risk of infectious complications. Wound infections following a hernia repair are a significant risk factor for hernia recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11268?source=see_link\">",
"     \"Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors and strategies to reduce the risk of infection after an inguinal and ventral abdominal wall hernia repair will be reviewed here. An overview of control measures to prevent surgical site infection (SSI) and control measure controversies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"     \"Controversies in control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537601\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical and technical factors have been identified that increase the risk of wound infection following an abdominal wall hernia repair, including clinical and intraoperative factors, use of mesh, location of mesh insertion, technique of hernia repair, use of drains, and emergent indications for procedure. Prior wound infections are also a risk factor since they are associated with a greater than 80 percent risk of hernia recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537617\">",
"    <span class=\"h2\">",
"     Clinical predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical risk factors associated with a wound infection in a hernia repair include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/1,3-7\">",
"     1,3-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Diabetes",
"     </li>",
"     <li>",
"      Immunosuppression",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1989458\">",
"    <span class=\"h2\">",
"     Intraoperative predictors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative risk factors associated with a wound infection in a hernia repair include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enterotomy",
"     </li>",
"     <li>",
"      Bowel resection",
"     </li>",
"     <li>",
"      Emergency procedure",
"     </li>",
"     <li>",
"      Prolonged operative time",
"     </li>",
"     <li>",
"      Perioperative blood transfusion",
"     </li>",
"     <li>",
"      Use of mesh to repair large ventral hernia defects (&gt;10 cm)",
"     </li>",
"     <li>",
"      Use of mesh in the setting of comorbid conditions such as diabetes, immunosuppression, or obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1984748\">",
"    <span class=\"h2\">",
"     Inguinal versus ventral hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective trials comparing the rate of infection following an inguinal hernia repair with a ventral hernia repair. It is generally accepted that ventral hernias have a higher risk of wound infection than inguinal hernias, although this depends extensively on the magnitude of the ventral hernia repair. &nbsp;The reported risk of a wound infection following an inguinal hernia repair ranges from 0 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/8-18\">",
"     8-18",
"    </a>",
"    ], while the reported risk of a wound infection following a ventral hernia repair ranges from 0 to 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/5,19-26\">",
"     5,19-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1987112\">",
"    <span class=\"h2\">",
"     Open versus laparoscopic technique of repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laparoscopic technique is associated with a lower risk of superficial wound infections for inguinal and ventral hernia repairs compared to the open technique. In contrast, there is no significant difference in deep wound infections necessitating mesh removal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 28 prospective trials with 5565 patients found that patients undergoing a laparoscopic",
"      <strong>",
"       inguinal",
"      </strong>",
"      hernia repair had a significantly lower rate of superficial wound infection compared with an open repair (OR 0.45, 95% CI 0.32-0.65) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/16\">",
"       16",
"      </a>",
"      ]. Deep wound infections are rare in patients undergoing laparoscopic or open inguinal hernia repair. In a meta-analysis of 22 prospective trials with 4654 patients undergoing an inguinal hernia repair, only three deep infections were reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of eight prospective trials with 526 patients found that laparoscopic",
"      <strong>",
"       ventral",
"      </strong>",
"      hernia repair with mesh was associated with significantly fewer superficial wound infections that did not require mesh removal (1.5 versus 10.1 percent) compared with an open repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/26\">",
"       26",
"      </a>",
"      ]. There were fewer deep wound infections reported that required mesh removal with laparoscopic repair (0.7 versus 3.5 percent), however, this difference was not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1984756\">",
"    <span class=\"h2\">",
"     Primary versus mesh repairs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data regarding whether the use of mesh during hernia repair imparts greater risk for infection than traditional repair without mesh. The reported risk of wound infection following an open or laparoscopic inguinal primary (without mesh) hernia repair ranges from 0 to 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/8-13\">",
"     8-13",
"    </a>",
"    ], while the reported risk of infection following a mesh repair ranges from 0.4 to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/5,15,19,20,22-28\">",
"     5,15,19,20,22-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11268?source=see_link\">",
"     \"Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 20 randomized trials with 5,016 patients undergoing",
"      <strong>",
"       inguinal",
"      </strong>",
"      hernia repair found no difference in infection rate between open mesh and open primary repairs (odds ratio 1.24, 95% CI 0.84-1.84) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/15\">",
"       15",
"      </a>",
"      ]. Virtually all infections were superficial.",
"     </li>",
"     <li>",
"      A review of two randomized trials with 341 patients found that the open suture repair technique for primary and incisional",
"      <strong>",
"       ventral",
"      </strong>",
"      hernias was associated with a lower pooled rate of infection compared with the open mesh repair (0 versus 10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/5,25\">",
"       5,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial including 93 patients comparing mesh or non-mesh repair for umbilical hernias reported increased rates of infection following mesh repair (28 versus 9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H411933\">",
"    <span class=\"h2\">",
"     Permanent versus absorbable mesh",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have been performed to determine the best prosthetic material for hernia repair. It appears that a permanent mesh is associated with fewer wound infections, whether placed by an open or laparoscopic technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/14,29-34\">",
"     14,29-34",
"    </a>",
"    ]. A multicenter retrospective review of 1500 cases of ventral hernia repair found significantly fewer infections with permanent mesh compared with absorbable mesh (4 versus 22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human acellular dermal matrix (HADM), a permanent allograft that is a structurally intact dermal matrix with a basement membrane complex, is used as a reinforcement to a repair or as a bridge repair for complex and routine ventral hernias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. A retrospective multi-institutional review of 241 patients undergoing a complex ventral hernia repair with HADM reported a surgical site infection (SSI) rate of 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/34\">",
"     34",
"    </a>",
"    ]. This high rate of infection was attributed to its use in repair of enterocutaneous fistulas, ostomy procedures, and other bowel procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412248\">",
"    <span class=\"h2\">",
"     Location of mesh placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesh can be placed above the fascia (onlay technique), below the fascia and muscular layers but above the peritoneum (sublay technique), or directly beneath the peritoneum (intraperitoneal sublay) (",
"    <a class=\"graphic graphic_figure graphicRef82341 \" href=\"mobipreview.htm?39/17/40210\">",
"     figure 1",
"    </a>",
"    ). In either onlay or sublay positions the fascia may be left open or closed if this can be accomplished without excessive tension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24151?source=see_link&amp;anchor=H12#H12\">",
"     \"Parastomal hernia\", section on 'Intraabdominal repair with mesh'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Location of mesh in the hernia repair was not associated with an increased risk of wound infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective trial evaluated 41 patients with massive ventral hernias who were treated with either an onlay mesh repair or a sublay mesh repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/35\">",
"       35",
"      </a>",
"      ]. There were only two superficial wound infections in this study.",
"     </li>",
"     <li>",
"      In a retrospective review of 175 patients with polypropylene, polyester, or e-PFTE mesh ventral hernia repair, there was no significant association with rate of infection and placement of the mesh in the intraperitoneal position (9 percent), preperitoneal sublay position (5 percent), or the in the retromuscular (a sublay variant) position (6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/19\">",
"       19",
"      </a>",
"      ]. For those patients who were treated with a mesh in the sublay position, the risk of infection was significantly lower when the fascia was closed over a sublay mesh placement (2 versus 18 percent) compared with mesh repairs that could not be covered by fascia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537625\">",
"    <span class=\"h2\">",
"     Drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of drains following a hernia repair is controversial. A retrospective review of 250 patients undergoing ventral hernia repairs with or without mesh found a significant increased risk of wound infections with drains compared with repairs without drains (19 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537633\">",
"    <span class=\"h2\">",
"     Incarceration, strangulation, and bowel resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the use of non-absorbable mesh for incisional hernia repair in potentially contaminated surgical settings. However, many studies support the use of a prosthetic mesh, such as polypropylene, in cases of acute incarceration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bowel resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective observational study of 95 patients with an acutely incarcerated",
"      <strong>",
"       groin",
"      </strong>",
"      hernia and hernia repair with non-absorbable mesh and a bowel resection reported only one wound infection in the study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review of 75 patients with a strangulated",
"      <strong>",
"       inguinal",
"      </strong>",
"      hernia found no significant difference for rates of wound infection for patients treated with a tension-free repair with polypropylene mesh compared to those treated with a modified Bassini (primary) repair (6.1 versus 9.5 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9465?source=see_link\">",
"       \"Inguinal and femoral hernia repair: Open techniques\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26393?source=see_link\">",
"       \"Inguinal and femoral hernia repair: Laparoscopic techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A randomized trial of 42 patients with an acutely incarcerated",
"      <strong>",
"       para-umbilical",
"      </strong>",
"      hernia found no significant difference in rates of wound infection for patients treated with an onlay polypropylene mesh compared with tissue repair (9.5 versus 14.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11693600\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of prosthetic implant infections involves a complex interaction between the foreign material, the bacteria, and the host immune response. In animal models, the presence of a subcutaneous foreign body reduces the minimal inoculum of Staphylococcus aureus required to cause infection by a factor of more than 100,000, to as little as 100 colony-forming units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/41\">",
"     41",
"    </a>",
"    ]. A general discussion on the principles of infections associated with implants can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42678?source=see_link\">",
"     \"Breast implant infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Host risk for infection may be increased in the setting of a foreign material for several reasons. Sites of foreign material have reduced microcirculation, which is important for host defense and delivery of antibiotics. In addition, the interaction of neutrophils with the foreign body diminishes neutrophil function, enhancing susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537641\">",
"    <span class=\"h1\">",
"     PREVENTION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies to prevent a surgical site infection (SSI) following a hernia repair include skin preparation (eg, patient bathing, hair removal, and preoperative skin antisepsis) are the same as for the prevention of infection at other surgical sites. The use of intravenous antibiotics for hernia repair is generally limited to repairs using mesh. The preferred antibiotics are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g) or, if the patient is allergic to penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g). The general principles and antimicrobial prophylaxis to prevent SSI are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'General principles'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537657\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotic usage in elective hernia repair is controversial. The 2009 Medical Letter guideline consultants do not recommend prophylaxis for such procedures due to the low rate of infection, low morbidity if infection does occur, and the potential adverse effect of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/43\">",
"     43",
"    </a>",
"    ]. However, experts recommend prophylaxis with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g) or, in the patient is allergic to penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g) for procedures that involve placement of prosthetic material such as synthetic mesh. In general, infected wounds with mesh necessitate removal of the mesh and therefore are more challenging to manage than infected wounds without mesh. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis of 13 randomized trials and 6825 patients found a 1.4 and 1.5 percent fewer wound infection rates with prophylactic antibiotics for hernia repairs with and without mesh, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/44\">",
"     44",
"    </a>",
"    ]. The results of the meta-analysis are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients undergoing a hernia repair with mesh (hernioplasty) and prophylactic antibiotics had significantly fewer SSI (1.4 versus 2.9 percent, OR 0.48, 95% CI 0.27 - 0.85) compared with patients undergoing a hernioplasty without prophylactic antibiotics.",
"     </li>",
"     <li>",
"      Patients undergoing a hernia repair without mesh (herniorrhaphy) and prophylactic antibiotics had fewer SSI (3.5 versus 4.9 percent, OR 0.71, 95% CI 0.51 - 1.00) compared with patients undergoing a herniorrhaphy without prophylactic antibiotics. This difference did not reach statistical significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537665\">",
"    <span class=\"h3\">",
"     Timing of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of antibiotic administration in hernia repair corresponds to that in any surgery using prophylactic antibiotics (",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"mobipreview.htm?22/46/23275\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537673\">",
"    <span class=\"h3\">",
"     Antibiotic choices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general parameters for intravenous antibiotic prophylaxis to prevent a SSI are discussed elsewhere (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"mobipreview.htm?23/52/24397\">",
"     table 2",
"    </a>",
"    ). For routine surgical procedures without open bowel that require prophylaxis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g) are used to reduce the risk of S. aureus and S. epidermis. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antibiotic selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative methods to standard intravenous administration of antibiotics for providing prophylaxis against an SSI include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irrigation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      solution &mdash; Irrigation with a solution containing 80 mg of gentamicin sulfate dissolved in 250 mL of isotonic saline immediately after opening the external oblique aponeurosis and continuing intermittently until the skin was closed reduced the risk of wound infection following an inguinal hernioplasty (repair with mesh) in a single institution over a period of 25 years. A prospective review of 4300 consecutive clean inguinal hernioplasties found no wound infections following irrigation with a gentamicin solution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/45\">",
"       45",
"      </a>",
"      ]. All patients also received preoperative intravenous injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (1 g) or, if the patients are allergic to penicillin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 g).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      -laced collagen tampon &mdash; A gentamicin-laced collagen tampon placed between the mesh and the external oblique muscle reduces the risk of an inguinal hernia SSI. A randomized trial of 595 patients undergoing an inguinal hernioplasty and treated with a gentamicin-laced collagen tampon found a significantly lower rate of wound infections (0.3 versus 2.0 percent) compared with untreated controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Silver",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      coating in Dual Mesh&reg; Plus &mdash; The application of silver chlorhexidine coating in Dual Mesh&reg; Plus biomaterial has also been reported to decrease the susceptibility to mesh infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/47\">",
"       47",
"      </a>",
"      ]. In a retrospective review of 120 patients undergoing laparoscopic ventral hernia repair with expanded polytetrafluoroethylene (ePTFE) impregnated with",
"      <span class=\"nowrap\">",
"       silver/chlorhexidine",
"      </span>",
"      Dual Mesh Plus (DM+) or ePTFE Dual Mesh (DM), there was only one SSI in the DM group and none in the DM+ group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43239/abstract/48\">",
"       48",
"      </a>",
"      ]. However, patients treated with DM+ were significantly more likely to have a postoperative noninfectious fever (38 versus 18 percent) and a significantly longer postoperative hospital stay (5 versus 3 days) compared with patients treated with DM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32537554\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernia repair is generally considered a &ldquo;clean procedure&rdquo; with a low risk of infectious complications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical risk factors associated with a wound infection in a hernia repair include obesity, diabetes, and smoking. (See",
"      <a class=\"local\" href=\"#H32537617\">",
"       'Clinical predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraoperative risk factors associated with a wound infection in a hernia repair include an enterotomy, bowel resection, and an emergent procedure. (See",
"      <a class=\"local\" href=\"#H1989458\">",
"       'Intraoperative predictors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laparoscopic technique is associated with a lower risk of superficial wound infections for inguinal and ventral hernia repairs compared with the open technique. In contrast, there is no significant difference in deep wound infections that require mesh removal. (See",
"      <a class=\"local\" href=\"#H1987112\">",
"       'Open versus laparoscopic technique of repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are conflicting data regarding whether the use of mesh during hernia repair imparts greater risk for infection than traditional repair without mesh. (See",
"      <a class=\"local\" href=\"#H1984756\">",
"       'Primary versus mesh repairs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When performing a hernioplasty (hernia repair with mesh), we suggest intravenous antibiotic prophylaxis with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (1 g) or, if the patient is allergic to penicillin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 g) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Patients undergoing a hernia repair with mesh (hernioplasty) and prophylactic antibiotics had significantly fewer SSI (1.4 versus 2.9 percent) compared with patients undergoing a hernioplasty without prophylactic antibiotics. (See",
"      <a class=\"local\" href=\"#H32537657\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/1\">",
"      Finan KR, Vick CC, Kiefe CI, et al. Predictors of wound infection in ventral hernia repair. Am J Surg 2005; 190:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/2\">",
"      Luijendijk RW, Hop WC, van den Tol MP, et al. A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med 2000; 343:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/3\">",
"      R&iacute;os A, Rodr&iacute;guez JM, Munitiz V, et al. Antibiotic prophylaxis in incisional hernia repair using a prosthesis. Hernia 2001; 5:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/4\">",
"      White TJ, Santos MC, Thompson JS. Factors affecting wound complications in repair of ventral hernias. Am Surg 1998; 64:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/5\">",
"      Korenkov M, Sauerland S, Arndt M, et al. Randomized clinical trial of suture repair, polypropylene mesh or autodermal hernioplasty for incisional hernia. Br J Surg 2002; 89:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/6\">",
"      Stremitzer S, Bachleitner-Hofmann T, Gradl B, et al. Mesh graft infection following abdominal hernia repair: risk factor evaluation and strategies of mesh graft preservation. A retrospective analysis of 476 operations. World J Surg 2010; 34:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/7\">",
"      Deysine M. Pathophysiology, prevention, and management of prosthetic infections in hernia surgery. Surg Clin North Am 1998; 78:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/8\">",
"      Pokorny H, Klingler A, Schmid T, et al. Recurrence and complications after laparoscopic versus open inguinal hernia repair: results of a prospective randomized multicenter trial. Hernia 2008; 12:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/9\">",
"      Gravante G, Venditti D, Filingeri V. The role of single-shot antibiotic prophylaxis in inguinal hernia repair: a meta-analysis approach of 4336 patients. Ann Surg 2008; 248:496.",
"     </a>",
"    </li>",
"    <li>",
"     Wake, B. L., McCormack, K., Fraser, C., Vale, L., Perez, J., and Grant, A. M. Transabdominal pre-peritoneal (TAPP) vs totally extraperitoneal (TEP) laparoscopic techniques for inguinal hernia repair. Cochrane.Database.Syst.Rev. 1-25-2005;CD004703.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/11\">",
"      McCormack K, Wake BL, Fraser C, et al. Transabdominal pre-peritoneal (TAPP) versus totally extraperitoneal (TEP) laparoscopic techniques for inguinal hernia repair: a systematic review. Hernia 2005; 9:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/12\">",
"      Legnani GL, Rasini M, Pastori S, Sarli D. Laparoscopic trans-peritoneal hernioplasty (TAPP) for the acute management of strangulated inguino-crural hernias: a report of nine cases. Hernia 2008; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/13\">",
"      Neumayer L, Giobbie-Hurder A, Jonasson O, et al. Open mesh versus laparoscopic mesh repair of inguinal hernia. N Engl J Med 2004; 350:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/14\">",
"      National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/15\">",
"      Grant AM, EU Hernia Trialists Collaboration. Open mesh versus non-mesh repair of groin hernia: meta-analysis of randomised trials based on individual patient data [corrected]. Hernia 2002; 6:130.",
"     </a>",
"    </li>",
"    <li>",
"     McCormack, K, Scott, N, Go, PM, Ross, SJ, Grant, A. Collaboration the EU Hernia Trialists. Laparoscopic techniques",
"versus open techniques for inguinal hernia repair. Cochrane Database of Systematic Reviews 2003, No.: CD001785. DOI:",
"10.1002/14651858.CD001785.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/17\">",
"      Witkowski, P, Pirski, M, I, Adamonis, et al. Mesh plug versus Bassini operation: a randomized prospective study. Hernia 2000; 4:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/18\">",
"      Amid, PK. Classification of biomaterials and their related complications in abdominal wall hernia surgery. Hernia 1997; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/19\">",
"      Petersen S, Henke G, Zimmermann L, et al. Ventral rectus fascia closure on top of mesh hernia repair in the sublay technique. Plast Reconstr Surg 2004; 114:1754.",
"     </a>",
"    </li>",
"    <li>",
"     den Hartog D, Dur AHM, Tuinebreijer WE, Kreis RW. Open surgical procedures for incisional hernias. Cochrane Database of Systematic Reviews 2008, No.: CD006438. DOI: 10.1002/14651858.CD006438.pub2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/21\">",
"      Dur AH, den Hartog D, Tuinebreijer WE, et al. Low recurrence rate of a two-layered closure repair for primary and recurrent midline incisional hernia without mesh. Hernia 2009; 13:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/22\">",
"      Pierce RA, Spitler JA, Frisella MM, et al. Pooled data analysis of laparoscopic vs. open ventral hernia repair: 14 years of patient data accrual. Surg Endosc 2007; 21:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/23\">",
"      Carlson MA, Frantzides CT, Shostrom VK, Laguna LE. Minimally invasive ventral herniorrhaphy: an analysis of 6,266 published cases. Hernia 2008; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/24\">",
"      Itani KM, Hur K, Kim LT, et al. Comparison of laparoscopic and open repair with mesh for the treatment of ventral incisional hernia: a randomized trial. Arch Surg 2010; 145:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/25\">",
"      Burger JW, Luijendijk RW, Hop WC, et al. Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. Ann Surg 2004; 240:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/26\">",
"      Forbes SS, Eskicioglu C, McLeod RS, Okrainec A. Meta-analysis of randomized controlled trials comparing open and laparoscopic ventral and incisional hernia repair with mesh. Br J Surg 2009; 96:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/27\">",
"      Cobb WS, Kercher KW, Heniford BT. Laparoscopic repair of incisional hernias. Surg Clin North Am 2005; 85:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/28\">",
"      Perrone JM, Soper NJ, Eagon JC, et al. Perioperative outcomes and complications of laparoscopic ventral hernia repair. Surgery 2005; 138:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/29\">",
"      Leber GE, Garb JL, Alexander AI, Reed WP. Long-term complications associated with prosthetic repair of incisional hernias. Arch Surg 1998; 133:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/30\">",
"      Martin DF, Williams RF, Mulrooney T, Voeller GR. Ventralex mesh in umbilical/epigastric hernia repairs: clinical outcomes and complications. Hernia 2008; 12:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/31\">",
"      Alaedeen DI, Lipman J, Medalie D, Rosen MJ. The single-staged approach to the surgical management of abdominal wall hernias in contaminated fields. Hernia 2007; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/32\">",
"      Misra MC, Kumar S, Bansal VK. Total extraperitoneal (TEP) mesh repair of inguinal hernia in the developing world: comparison of low-cost indigenous balloon dissection versus direct telescopic dissection: a prospective randomized controlled study. Surg Endosc 2008; 22:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/33\">",
"      Candage R, Jones K, Luchette FA, et al. Use of human acellular dermal matrix for hernia repair: friend or foe? Surgery 2008; 144:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/34\">",
"      Diaz JJ Jr, Conquest AM, Ferzoco SJ, et al. Multi-institutional experience using human acellular dermal matrix for ventral hernia repair in a compromised surgical field. Arch Surg 2009; 144:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/35\">",
"      Afifi RY. A prospective study between two different techniques for the repair of a large recurrent ventral hernia: a double mesh intraperitoneal repair versus onlay mesh repair. Hernia 2005; 9:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/36\">",
"      Geisler DJ, Reilly JC, Vaughan SG, et al. Safety and outcome of use of nonabsorbable mesh for repair of fascial defects in the presence of open bowel. Dis Colon Rectum 2003; 46:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/37\">",
"      Birolini C, Utiyama EM, Rodrigues AJ Jr, Birolini D. Elective colonic operation and prosthetic repair of incisional hernia: does contamination contraindicate abdominal wall prosthesis use? J Am Coll Surg 2000; 191:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/38\">",
"      Atila K, Guler S, Inal A, et al. Prosthetic repair of acutely incarcerated groin hernias: a prospective clinical observational cohort study. Langenbecks Arch Surg 2010; 395:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/39\">",
"      Papaziogas B, Lazaridis Ch, Makris J, et al. Tension-free repair versus modified Bassini technique (Andrews technique) for strangulated inguinal hernia: a comparative study. Hernia 2005; 9:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/40\">",
"      Abdel-Baki NA, Bessa SS, Abdel-Razek AH. Comparison of prosthetic mesh repair and tissue repair in the emergency management of incarcerated para-umbilical hernia: a prospective randomized study. Hernia 2007; 11:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/41\">",
"      Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982; 146:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/42\">",
"      Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest 1984; 73:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/43\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2009; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/44\">",
"      Sanchez-Manuel FJ, Lozano-Garc&iacute;a J, Seco-Gil JL. Antibiotic prophylaxis for hernia repair. Cochrane Database Syst Rev 2007; :CD003769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/45\">",
"      Deysine M. Infection control in a hernia clinic: 24 year results of aseptic and antiseptic measure implementation in 4,620 \"clean cases\". Hernia 2006; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/46\">",
"      Musella M, Guido A, Musella S. Collagen tampons as aminoglycoside carriers to reduce postoperative infection rate in prosthetic repair of groin hernias. Eur J Surg 2001; 167:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/47\">",
"      Harrell AG, Novitsky YW, Kercher KW, et al. In vitro infectability of prosthetic mesh by methicillin-resistant Staphylococcus aureus. Hernia 2006; 10:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43239/abstract/48\">",
"      Cobb WS, Paton BL, Novitsky YW, et al. Intra-abdominal placement of antimicrobial-impregnated mesh is associated with noninfectious fever. Am Surg 2006; 72:1205.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15100 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43239=[""].join("\n");
var outline_f42_14_43239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32537554\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32537546\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32537601\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32537617\">",
"      Clinical predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1989458\">",
"      Intraoperative predictors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1984748\">",
"      Inguinal versus ventral hernias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1987112\">",
"      Open versus laparoscopic technique of repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1984756\">",
"      Primary versus mesh repairs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H411933\">",
"      Permanent versus absorbable mesh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412248\">",
"      Location of mesh placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32537625\">",
"      Drains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32537633\">",
"      Incarceration, strangulation, and bowel resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11693600\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32537641\">",
"      PREVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32537657\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32537665\">",
"      - Timing of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32537673\">",
"      - Antibiotic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32537554\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15100|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/17/40210\" title=\"figure 1\">",
"      Abdominal wall mesh placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15100|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/46/23275\" title=\"table 1\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/52/24397\" title=\"table 2\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42678?source=related_link\">",
"      Breast implant infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11268?source=related_link\">",
"      Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/49/26393?source=related_link\">",
"      Inguinal and femoral hernia repair: Laparoscopic techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9465?source=related_link\">",
"      Inguinal and femoral hernia repair: Open techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24151?source=related_link\">",
"      Parastomal hernia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_14_43240="Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis";
var content_f42_14_43240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43240/contributors\">",
"     Andrew Arnold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43240/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43240/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/14/43240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant predisposition to tumors of the parathyroid glands (which occur in nearly all patients by age 50 years), anterior pituitary, and entero-pancreatic endocrine cells; hence, the mnemonic device of the \"3 Ps\" (",
"    <a class=\"graphic graphic_table graphicRef53057 \" href=\"mobipreview.htm?19/40/20108\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the clinical spectrum of this disorder has been expanded. The duodenum is a common site of tumors (gastrinomas) in these patients, and carcinoid tumors, adrenal adenomas, and lipomas are more common than in the general population (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of MEN1 will be reviewed here. The genetics of this disorder, its distinction from other MEN syndromes, and its treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF MEN1",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN1 is a rare heritable disorder classically characterized by a predisposition to tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of MEN1 is defined clinically as the occurrence of two or more primary MEN1 tumor types, or in family members of a patient with a clinical diagnosis of MEN1, the occurrence of one of the MEN1 associated tumors. It should be noted that these are clinical definitions and do not necessarily indicate that mutation of the MEN1 gene will be identifiable or responsible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4058708\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Parathyroid adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple parathyroid adenomas causing hyperparathyroidism are the most common manifestation of MEN1, displaying almost 100 percent penetrance by age 40 to 50 years. In most cases, it is the initial manifestation of MEN1. Reliable incidence figures do not exist, but it has been estimated that the incidence of MEN1 ranges from 1 to 18 percent in patients with primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary hyperparathyroidism in the setting of familial MEN1 has a number of different features from the common sporadic (non-familial) form of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The male to female ratio is even in MEN1 in contrast to the female predominance in sporadic hyperparathyroidism.",
"     </li>",
"     <li>",
"      Hyperparathyroidism in MEN1 typically presents in the second to fourth decade of life, about two decades earlier than in sporadic hyperparathyroidism.",
"     </li>",
"     <li>",
"      Multiple adenomas are typical in MEN1, and given sufficient time, perhaps universal. In comparison, approximately 80 to 85 percent of patients with sporadic disease have single parathyroid adenomas. Upon initial neck exploration, however, some parathyroid glands in MEN1 may appear to be grossly normal. It is not known if these glands are truly normal or are examples of mild asymmetric hypercellularity.",
"     </li>",
"     <li>",
"      A strong and seemingly inexorable proliferative drive in parathyroid cells appears to exist in classical MEN1, as indicated by the high rate of recurrent hyperparathyroidism after apparently successful subtotal parathyroidectomy. One report from the National Institutes of Health, as an example, found a recurrence rate above 50 percent at 12 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/3\">",
"       3",
"      </a>",
"      ]; most other studies have had shorter follow-up periods. The high recurrence rate clearly distinguishes the hyperparathyroidism of MEN1 from that seen in sporadic disease. It has also resulted in differences of opinion with respect to optimal surgical management of this disorder. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to sporadic primary hyperparathyroidism, the majority of patients are asymptomatic, and hypercalcemia is detected by routine biochemical screening. If clinical manifestations of primary hyperparathyroidism are present, they may include decreased bone mineral density, kidney stones, and symptoms of hypercalcemia (polyuria, polydipsia, constipation). The biochemical diagnosis of primary hyperparathyroidism is based, as it is in all patients with primary hyperparathyroidism, on the demonstration of hypercalcemia with inappropriately high serum parathyroid hormone (PTH) concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=see_link\">",
"     \"Diagnosis and differential diagnosis of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pituitary adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically apparent pituitary adenomas have been found in approximately 15 to 20 percent of patients with MEN1 when sought by CT or MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/4\">",
"     4",
"    </a>",
"    ] and 42 percent in a multicenter study of 324 MEN1 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/5\">",
"     5",
"    </a>",
"    ]. The pathological prevalence in one series was over 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/6\">",
"     6",
"    </a>",
"    ]. The pituitary cell type is similar to that found in sporadic pituitary adenomas. Thus, the most common type of pituitary adenoma in MEN1 is lactotroph, but somatotroph, corticotroph, gonadotroph, and clinically nonfunctioning tumors can also occur (",
"    <a class=\"graphic graphic_table graphicRef53057 \" href=\"mobipreview.htm?19/40/20108\">",
"     table 1",
"    </a>",
"    ). Multiple pituitary tumors are rarely present in MEN1.",
"   </p>",
"   <p>",
"    The phenotypic presentation of pituitary disease is variable. In one large kindred, as an example, lactotroph adenomas predominated, and none of the 165 patients had acromegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Furthermore, the distribution of lactotroph adenomas was not even; the prevalence was more than 50 percent in some branches of the kindred and very low in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter study of 324 MEN1 patients (42 percent of whom had pituitary tumors), compared with 110 non-MEN patients with pituitary adenomas, revealed that [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 136 MEN1 patients with pituitary adenomas, 85 percent had macroadenomas (versus 42 percent in non-MEN1 patients).",
"     </li>",
"     <li>",
"      In the same patients, hormonal hypersecretion was normalized in 42 percent after treatment versus 90 percent in non-MEN1 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The MEN1 patients had adenomas that were larger and more aggressive than those in non-MEN patients. Whether these findings will be confirmed and whether a program of routine surveillance by imaging would decrease morbidity from pituitary disease in MEN1 remains unknown.",
"   </p>",
"   <p>",
"    The clinical manifestations, approach to diagnosis, and therapy of pituitary adenomas in patients with MEN1 is similar to that in patients with sporadic adenomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes, presentation, and evaluation of sellar masses\", section on 'Pituitary adenomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pancreatic islet cell/gastrointestinal adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functioning pancreatic islet cell or gastrointestinal endocrine cell tumors become clinically apparent in approximately one-third of patients with MEN1. The most common cause of symptomatic disease is the Zollinger-Ellison (gastrinoma) syndrome (ZES), leading to multiple peptic ulcers. It has been estimated that 60 percent of patients with MEN1 have either the Zollinger-Ellison syndrome or asymptomatic elevation in serum gastrin concentrations; on the other hand, MEN1 is present in 20 to 60 percent of patients with the Zollinger-Ellison syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/9\">",
"     9",
"    </a>",
"    ]. Symptomatic insulinomas also occur with moderate frequency, while VIPomas and glucagonomas are rare (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=see_link\">",
"     \"Glucagonoma and the glucagonoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of radiographically confirmed nonfunctioning tumors is similar to that of gastrinomas, ranging from 30 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Like hormonally active enteropancreatic tumors in MEN1, clinically \"nonfunctioning\" PETs may be malignant and capable of causing liver metastases. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Nonfunctioning pancreatic tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Effective treatment is usually available for the hyperparathyroidism and pituitary disease in MEN1; as a result, the malignant potential of pancreatic endocrine tumors (PETs) is now the primary life-threatening manifestation of MEN1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Zollinger-Ellison syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, attempts at surgical cure of the hypergastrinemia in the Zollinger-Ellison syndrome in patients with MEN1 were uniformly unsuccessful. It is now apparent that the basis for the failure of these approaches, namely resection of palpable tumors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    partial pancreatectomy, is due to the biological nature and characteristics of the tumors in MEN1. In contrast to sporadically occurring gastrinomas, the gastrinomas in MEN1 patients are multifocal, often exceedingly small, and easily overlooked. In addition, the duodenum is a common site of gastrinomas both in MEN1 and in sporadic gastrinoma&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/9,14,15\">",
"     9,14,15",
"    </a>",
"    ]; in comparison, the tumors that are found in the pancreas do not usually secrete gastrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of death from malignant spread of MEN1-associated gastrinoma appears to be less than that for sporadic gastrinoma. Local lymph node metastases are common, but are not necessarily associated with a poor prognosis or a high likelihood that clinically important metastases will occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one large series, investigators at the National Institutes of Health prospectively followed 107 patients with MEN1 and Zollinger-Ellison syndrome, and reviewed 1009 cases from the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/17\">",
"     17",
"    </a>",
"    ]. Their findings were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 25 percent of",
"      <span class=\"nowrap\">",
"       MEN1/ZES",
"      </span>",
"      patients had no family history of MEN1.",
"     </li>",
"     <li>",
"      Zollinger-Ellison syndrome was the initial clinical manifestation of MEN1 in 40 percent of patients with",
"      <span class=\"nowrap\">",
"       MEN1/ZES.",
"      </span>",
"     </li>",
"     <li>",
"      The onset of ZES symptoms preceded the diagnosis of hyperparathyroidism in 45 percent of patients.",
"     </li>",
"     <li>",
"      The diagnosis of ZES was delayed for three to six years after its onset.",
"     </li>",
"     <li>",
"      Pituitary disease occurred in 60 percent of patients.",
"     </li>",
"     <li>",
"      In patients without a family history of MEN1, ZES and other MEN1 manifestations occurred later and were less severe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypersecretion of gastrin in the Zollinger-Ellison syndrome in MEN1 may be suspected clinically by the presence of multiple peptic ulcers (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57632 \" href=\"mobipreview.htm?0/25/404\">",
"     image 1",
"    </a>",
"    ) or symptoms like diarrhea. The diagnosis is confirmed by the same biochemical and gastric acid output criteria as are used in the sporadic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .) Hypercalcemia from coexisting hyperparathyroidism can significantly exacerbate the symptoms of Zollinger-Ellison syndrome, and parathyroidectomy to correct hypercalcemia can reduce fasting and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulated gastrin levels and basal acid secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of Cushing's syndrome has been reported to be increased in patients with Zollinger-Ellison syndrome. When Cushing's syndrome occurs in patients with nonfamilial gastrinoma, the usual cause is ectopic ACTH release from the islet-cell tumor. These cases are associated with severe symptoms. In contrast, patients with familial MEN1 and Zollinger-Ellison syndrome who develop Cushing's syndrome usually have a corticotroph adenoma of the pituitary and relatively mild symptoms of cortisol excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Insulinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin-producing pancreatic islet cell adenomas in MEN1 are often small, may be multiple, and may be associated with the simultaneous presence of other islet cell tumors. Insulinoma in MEN1 typically presents in the second to fourth decade of life, earlier than in sporadic insulinoma, which usually occurs in individuals older than 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of insulinoma depends, as in nonfamilial causes, upon the documentation of hypoglycemia with characteristic symptoms that are rapidly reversed by the administration of glucose, and inappropriately high serum insulin concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nonfunctioning pancreatic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize that pancreatic islet cell tumors in MEN1 often synthesize multiple hormones. But hormone synthesis does not always have clinical consequences, suggesting that many such tumors may be defective in their peptide hormone processing apparatus or have an inefficient secretory mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/22\">",
"     22",
"    </a>",
"    ]. Like hormonally active enteropancreatic tumors in MEN1, clinically \"nonfunctioning\" pancreatic endocrine tumors (PETs) may be malignant and can metastasize to the liver. Nonfunctioning PETs have been detected as early as ages 12 to 14 in asymptomatic children with MEN1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonfunctioning PETs are among the most common tumor of the pancreaticoduodenal region in patients with MEN1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In a report of 579 MEN1 patients, 108 patients with isolated nonfunctioning PETs were identified with the following clinical characteristics and course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The penetrance of nonfunctioning PET was 34 percent at age 50 years.",
"     </li>",
"     <li>",
"      The risks of metastasis and death were low for patients with tumors &le;20 mm.",
"     </li>",
"     <li>",
"      Average life expectancy for nonfunctioning PET patients was similar to that for gastrinoma patients (69 to 70 years) and shorter than that for patients without pancreatic tumors (77 years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best way to detect these nonfunctioning tumors is unclear. A limited amount of data suggests that endoscopic ultrasound outperforms CT scanning in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=see_link&amp;anchor=H12145121#H12145121\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Endoscopic ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other tumors also occur with increased frequency in MEN1. These include carcinoid, cutaneous tumors, adrenal tumors (especially nonfunctional adrenocortical adenomas), gastric enterochromaffin-like cell carcinoids, pheochromocytoma (very rarely), angiomyolipomas, meningiomas, and spinal cord ependymomas (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic carcinoid tumors occur with increased frequency in MEN1 (2.6 to 5 percent in retrospective series of patients with MEN1), mostly in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Heavy smoking may be a risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/24\">",
"     24",
"    </a>",
"    ]. Carcinoids in women with MEN1 are most often bronchial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thymic carcinoids, the most common cause of anterior mediastinal masses in MEN1, are typically nonfunctional (in contrast to the substantial incidence of ectopic Cushing's syndrome in patients with sporadic thymic carcinoid), and tend to be aggressive (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A prospective study of thymic carcinoids in 85 patients with MEN1 evaluated for pancreatic endocrine tumors and followed for a mean of eight years (with serial chest CT, MRI, and somatostatin receptor scintigraphy [SRS]) reported the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven patients (8 percent) developed thymic carcinoids, all of which were hormonally inactive.",
"     </li>",
"     <li>",
"      All seven patients were male, and Zollinger-Ellison syndrome was present in six.",
"     </li>",
"     <li>",
"      Five of the seven were asymptomatic, one had cough, and one had chest pain.",
"     </li>",
"     <li>",
"      CT and MRI were more sensitive than SRS for detecting the tumors initially or with recurrence.",
"     </li>",
"     <li>",
"      All patients underwent surgical resection. All four patients followed for more than one year post-operatively had tumor recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some have recommended regular screening, by chest imaging studies, for this tumor in men with MEN1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. However, given the rarity of these tumors and the unproven survival benefits of this approach, we consider such routine screening reasonable, but not mandatory. Certainly, it seems prudent to strongly advise men with definite or possible MEN1 against smoking, to take into consideration a strong family history of carcinoid tumors, and to perform prophylactic thymectomy in patients undergoing parathyroidectomy, although even this measure does not fully prevent subsequent development of thymic neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric carcinoids and enterochromaffin-like cell proliferation (a precursor lesion of gastric carcinoid) have been reported in patients with MEN1 and ZES. In a prospective study of 57 patients with MEN1 and ZES, advanced enterochromaffin-like cell proliferation and gastric carcinoid were detected in 53 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/29\">",
"     29",
"    </a>",
"    ]. Long duration of ZES, long duration of medical treatment, high fasting serum gastrin levels, and the presence of gastric nodules on gastroscopy were associated with a higher risk of gastric carcinoid. Such patients may benefit from regular monitoring for gastric carcinoid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Stomach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cutaneous tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous tumors are common in MEN1 (",
"    <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/30\">",
"     30",
"    </a>",
"    ]; their presence in patients with pancreatic endocrine tumors suggest the diagnosis of MEN1. This was illustrated in a prospective study of 110 consecutive patients with gastrinoma (48 with MEN1 and 62 without MEN1) with the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiofibromas and collagenomas were more common in MEN1 patients than in those without MEN1 (64 versus 8 percent, and 62 versus 5 percent, respectively).",
"     </li>",
"     <li>",
"      These cutaneous tumors were multiple in 77 to 81 percent of MEN1 patients; lipomas were present in 17 percent.",
"     </li>",
"     <li>",
"      The combination criterion of more than three angiofibromas and any collagenomas had a sensitivity of 75 percent and a specificity of 95 percent for the diagnosis on MEN1. The sensitivity and specificity of this criterion compares favorably to the finding of hyperparathyroidism in patients who present initially with gastrinomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, the presence of angiofibromas or collagenomas can be helpful clinically in suggesting the diagnosis of MEN1 in selected patients with primary hyperparathyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4058938\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of MEN1 is based upon the occurrence of two or more primary MEN1 tumor types (parathyroid gland, anterior pituitary, and pancreatic islet cells). In family members of a patient with a clinical diagnosis of MEN1, the occurrence of one of the MEN1 associated tumors is consistent with familial MEN1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of MEN1 (or at least a determination that an individual is genetically predisposed to developing MEN1 clinically) can also be made by identifying a germline MEN1 mutation in an individual in whom the clinical diagnosis of MEN1 is not clearly established or in an asymptomatic family member who has not yet developed the serum biochemical or radiological abnormalities associated with tumor development. (See",
"    <a class=\"local\" href=\"#H14907247\">",
"     'Confirming the diagnosis of MEN1'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H24809205\">",
"     'Screening of family members in MEN1 kindreds'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DNA TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct DNA testing for MEN1 gene mutations is available in academic and commercial laboratories (ie,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests",
"    </a>",
"    ). Generally speaking, DNA testing can have utility in several linked ways including: confirming the clinical diagnosis of the syndrome in a proband; examining a clearly affected proband to determine if mutation-specific carrier testing can be offered to relatives in that family; definitively determining whether or not asymptomatic or other relatives of a proband carry the mutant gene; and",
"    <span class=\"nowrap\">",
"     prenatal/preimplantation",
"    </span>",
"    diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Based upon these potential benefits, guidelines from an international group of endocrinologists recommend offering MEN1 mutational analysis to any index patient with clinical MEN1 (two or more primary MEN1 tumor types), all first-degree relatives of known MEN1 mutation carriers, and to individuals with suspicious or atypical MEN1 (eg, multiple parathyroid adenomas, gastrinoma, or multiple pancreatic neuroendocrine tumors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the optimal role of DNA testing in the context of MEN1 is not clear-cut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. In large part this is due to a dearth of solid data showing that preclinical detection of MEN1-related tumors leads to interventions that improve morbidity or mortality. This situation contrasts, for example, with the established value of RET DNA testing in MEN2 kindreds (",
"    <a class=\"graphic graphic_table graphicRef80814 \" href=\"mobipreview.htm?3/5/3164\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .) Nonetheless, there are circumstances in which DNA testing for MEN1 can be helpful and this option should be seriously considered. We make determinations regarding MEN1 DNA testing on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14907247\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis of MEN1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Situations in which DNA testing can be helpful may arise when the diagnosis of MEN1 is unable to be clearly established on clinical grounds and would alter management. Examples may include some patients with a suggestive family history who present with isolated primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/32\">",
"     32",
"    </a>",
"    ] or those with apparently sporadic Zollinger-Ellison syndrome, some of whom will have MEN1 mutation and would therefore be managed differently. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relevant factors to consider in these situations include the expected yield of testing, or likelihood of a positive result, which can vary markedly depending on the specific clinical presentation. For example, while MEN1 gene mutation is detectable in about 70 percent of kindreds with classic familial MEN1, the yield of testing drops to 7 percent in individuals with a sporadic presentation of combined hyperparathyroidism and pituitary adenoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/34\">",
"     34",
"    </a>",
"    ]. About 10 percent of kindreds with familial isolated hyperparathyroidism have a detectable MEN1 mutation, and yields can be even lower when less stringent criteria are selected, such as sporadic isolated hyperparathyroidism with age under 40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cost-benefit considerations can importantly influence decision-making. Sequencing costs remain substantial (and variably covered by insurance in the US), but are expected to decrease over time. It is also important to recognize that a negative result (mutation not detected) does not rule out the diagnosis of MEN1 nor the possibility that unidentified pathologic disruption of the MEN1 gene is responsible. Beyond assessing whether detection of an MEN1 mutation would impact a patient&rsquo;s immediate clinical management, factors influencing the decision to test include an examination of the potential utility of a positive finding for the purposes of family screening and one&rsquo;s approach to the prospective surveillance for MEN1-related tumors in the proband and family. (See",
"    <a class=\"local\" href=\"#H14907078\">",
"     'Screening for MEN1-associated tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24809205\">",
"    <span class=\"h2\">",
"     Screening of family members in MEN1 kindreds",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient is diagnosed as having MEN1, the issue of screening family members who are at risk often arises. In general, the primary and most compelling purpose of such screening in human tumor disposition syndromes is to prevent disease-related morbidity and mortality that would otherwise occur. However, there is at present little evidence that early, preclinical detection actually reduces overall morbidity or mortality in MEN1. Nonetheless, because benefit seems likely in some instances, and because other helpful information can potentially result, screening may be pursued and DNA-based testing merits serious consideration.",
"   </p>",
"   <p>",
"    We have a discussion about DNA testing with the index patient and appropriate family members, making decisions on a case-by-case basis. Involvement of a genetic counselor may be helpful. Proper informed consent must be obtained for each individual to be tested. If DNA-based family screening is to be pursued, the initial step is to test the MEN1 gene in a peripheral blood sample from the affected index case, if not already performed. If MEN1 sequencing of the affected patient does reveal a pathologic mutation, the presence or absence of this family-specific mutation can then be definitively determined in at-risk relatives. Thus, a significant potential benefit of such testing is the identification of family members who do not have the mutation and therefore do not need regular surveillance. The value of this benefit is enhanced to the extent that the clinician tends to opt for one of the more costly or intensive approaches to surveillance to detect MEN1-associated conditions in at-risk individuals. (See",
"    <a class=\"local\" href=\"#H14907078\">",
"     'Screening for MEN1-associated tumors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The presence of the mutation in an asymptomatic family member does not indicate the need for a major intervention, but does focus the need for regular surveillance (eg, assessment of symptoms, signs, biochemical tests) on these individuals. It is possible that an asymptomatic individual&rsquo;s knowledge that",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    definitely carries the disease gene may increase compliance with surveillance visits and testing. Other issues include genetic discrimination, which in the US remains a potential concern, despite certain protections in the Genetic Information Nondiscrimination Act of 2008. Approaches to DNA testing and screening can vary in different nations.",
"    <br/>",
"    <br/>",
"    Finally, knowledge of a family&rsquo;s specific MEN1 mutation can resolve the small potential for diagnostic confusion attributable to rare MEN1 phenocopies within MEN1 kindreds, namely individuals who can initially be classified as having the syndrome when they develop a typical tumor (eg, prolactinoma), but may then be proven by DNA testing to have not inherited the pathologic mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Thus, DNA-based screening can yield useful information, although it is certainly not mandatory. If DNA testing is not employed for screening asymptomatic family members, one low cost option is measurement of serum calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/4\">",
"     4",
"    </a>",
"    ]. This approach exploits the high penetrance of hyperparathyroidism in MEN1. In addition, adding measurements of serum PTH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ionized calcium and assuring the absence of vitamin D deficiency may improve sensitivity and specificity of screening. Also, as noted above, the presence of angiofibromas or collagenomas can be useful in this context.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14907078\">",
"    <span class=\"h1\">",
"     SCREENING FOR MEN1-ASSOCIATED TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with MEN1, known MEN1 carriers, and family members whose risk has not been eliminated by DNA testing, clinical vigilance should be maintained for symptoms or signs that could be due to MEN1-associated tumors. These include symptoms of nephrolithiasis, amenorrhea, galactorrhea, erectile dysfunction, peptic ulcer disease, diarrhea, and neuroglycopenic or sympathoadrenal symptoms from hypoglycemia. We typically measure serum calcium annually to detect asymptomatic hyperparathyroidism, which might be treated surgically.",
"   </p>",
"   <p>",
"    The extent to which additional surveillance for endocrine tumors, employing biochemical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic methods, should be used can be debated since evidence for their efficacy in improving outcomes is not strong [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/37\">",
"     37",
"    </a>",
"    ]. Nevertheless, some published guidelines have opted for pointing the clinician to a more aggressive screening protocol for MEN1-associated risks beginning at very early ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1,34\">",
"     1,34",
"    </a>",
"    ]. A 2012 paper, for example, while acknowledging weaknesses in available supporting data, suggested routine annual measurement of serum calcium parathyroid hormone, gastrin, fasting glucose, insulin, insulin-like growth factor-1, prolactin, and chromogranin-A, starting in childhood and continuing for life. Imaging tests (MRI of the pituitary and CT scan to evaluate for enteropancreatic tumors) were suggested every one to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"     1",
"    </a>",
"    ]. Others have recommended more limited biochemical testing and somewhat different imaging approaches (including endoscopic ultrasound) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that cost-effectiveness and risk-benefit considerations (including those related to diagnostic radiation exposure) can reasonably be taken into account in determining the prospective surveillance program of an individual with MEN1 or a family member at risk, beyond the maintenance of disease-focused clinical vigilance. For example, annual measurement of serum calcium offers the opportunity to inexpensively detect asymptomatic hyperparathyroidism, which might be treated surgically. Other combinations of biochemical and imaging surveillance, including those in published protocols, can reasonably be used but are not mandatory given the absence of support by high-quality evidence. New advances in treatment could dramatically alter these recommendations; for example, a future demonstration that an aggressive surgical approach to gastrinoma clearly improves disease-related mortality would provide a rationale for intensive biochemical and anatomic screening, which is capable of detecting gastrointestinal or pancreatic disease in asymptomatic family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43240/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28380297\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant predisposition to tumors of the parathyroid glands, anterior pituitary, and entero-pancreatic endocrine cells. MEN1 is defined as the presence of two of the three main MEN1 tumor types, or in family members of a patient with a clinical diagnosis of MEN1, the occurrence of one of the MEN1 associated tumors (",
"      <a class=\"graphic graphic_table graphicRef53057 \" href=\"mobipreview.htm?19/40/20108\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of men1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, multiple parathyroid adenomas causing primary hyperparathyroidism are the initial manifestation of MEN1, displaying almost 100 percent penetrance by age 40 to 50 years (",
"      <a class=\"graphic graphic_table graphicRef74208 \" href=\"mobipreview.htm?36/56/37772\">",
"       table 2",
"      </a>",
"      ). Similar to sporadic adenomas causing primary hyperparathyroidism, the majority of patients are asymptomatic, and hypercalcemia is detected by routine biochemical screening. The biochemical diagnosis of primary hyperparathyroidism is based, as it is in all patients with primary hyperparathyroidism, upon the demonstration of hypercalcemia with inappropriately high serum parathyroid hormone (PTH) concentrations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Parathyroid adenomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common type of pituitary adenoma in MEN1 is a lactotroph adenoma, but somatotroph, corticotroph, gonadotroph, and clinically nonfunctioning adenomas can also occur. The approach to diagnosis and therapy of pituitary adenomas in patients with MEN1 is similar to that in patients with sporadic adenomas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pituitary adenomas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=see_link&amp;anchor=H22#H22\">",
"       \"Causes, presentation, and evaluation of sellar masses\", section on 'Evaluation of a sellar mass'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functioning pancreatic islet cell or gastrointestinal endocrine cell tumors become clinically apparent in approximately one-third of patients with MEN1. The most common cause of symptomatic disease is the Zollinger-Ellison (gastrinoma) syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pancreatic islet cell/gastrointestinal adenomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DNA testing for MEN1 gene mutations is available commercially and can provide valuable information in specific situations, although its results generally do not dictate use of a major intervention established to improve morbidity or mortality. We make determinations regarding MEN1 DNA testing on a case-by-case basis. Biochemical screening (ie, serum calcium) of family members can be considered as a less costly alternative to genetic screening, given the high penetrance of primary hyperparathyroidism in MEN1, although its negative predictive value at younger ages is limited. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'DNA testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24809205\">",
"       'Screening of family members in MEN1 kindreds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We monitor all patients with MEN1, known MEN1 mutation carriers, and at risk family members with unknown carrier status for symptoms or signs of MEN1-associated tumors, such as nephrolithiasis, amenorrhea (women), galactorrhea, erectile dysfunction (men), peptic ulcer disease, diarrhea, and neuroglycopenic or sympathoadrenal symptoms from hypoglycemia. We typically measure serum calcium annually to detect asymptomatic hyperparathyroidism, which might be treated surgically. Additional surveillance using biochemical and imaging modalities can also be considered. (See",
"      <a class=\"local\" href=\"#H14907078\">",
"       'Screening for MEN1-associated tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/1\">",
"      Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97:2990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/2\">",
"      Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res 2009; 24:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/3\">",
"      Rizzoli, R, Green, J, Marx, SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type 1. Am J Med 1985; 78:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/4\">",
"      Burgess JR, Shepherd JJ, Parameswaran V, et al. Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred. J Clin Endocrinol Metab 1996; 81:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/5\">",
"      Verg&egrave;s B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002; 87:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/6\">",
"      Padberg B, Schr&ouml;der S, Capella C, et al. Multiple endocrine neoplasia type 1 (MEN 1) revisited. Virchows Arch 1995; 426:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/7\">",
"      Burgess JR, Shepherd JJ, Parameswaran V, et al. Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred. Am J Med 1996; 100:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/8\">",
"      Burgess JR, Shepherd JJ, Parameswaran V, et al. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. J Clin Endocrinol Metab 1996; 81:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/9\">",
"      Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/10\">",
"      Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/11\">",
"      Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/12\">",
"      Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/13\">",
"      Wamsteker EJ, Gauger PG, Thompson NW, Scheiman JM. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003; 58:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/14\">",
"      Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12:5440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/15\">",
"      Donow C, Pipeleers-Marichal M, Schr&ouml;der S, et al. Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 1991; 68:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/16\">",
"      Gibril F, Jensen RT. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/17\">",
"      Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/18\">",
"      Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/19\">",
"      Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/20\">",
"      Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 2008; 247:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/21\">",
"      Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with the Zollinger-Ellison syndrome. N Engl J Med 1986; 315:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/22\">",
"      Marx, SJ, Vinik, AI, Santen, RJ, et al. Multiple endocrine neoplasia type I: assessment of laboratory tests to screen for the gene in a large kindred. Medicine 1986; 65:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/23\">",
"      Newey PJ, Jeyabalan J, Walls GV, et al. Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2009; 94:3640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/24\">",
"      Teh BT, McArdle J, Chan SP, et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore) 1997; 76:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/25\">",
"      Goudet P, Murat A, Cardot-Bauters C, et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009; 33:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/26\">",
"      Doherty GM. Multiple endocrine neoplasia type 1. J Surg Oncol 2005; 89:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/27\">",
"      Gibril F, Chen YJ, Schrump DS, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003; 88:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/28\">",
"      Teh BT, Zedenius J, Kyt&ouml;l&auml; S, et al. Thymic carcinoids in multiple endocrine neoplasia type 1. Ann Surg 1998; 228:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/29\">",
"      Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab 2008; 93:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/30\">",
"      Darling TN, Skarulis MC, Steinberg SM, et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997; 133:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/31\">",
"      Asgharian B, Turner ML, Gibril F, et al. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004; 89:5328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/32\">",
"      Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/33\">",
"      Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr Pract 2011; 17 Suppl 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/34\">",
"      Agarwal SK, Ozawa A, Mateo CM, Marx SJ. The MEN1 gene and pituitary tumours. Horm Res 2009; 71 Suppl 2:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/35\">",
"      Skandarajah A, Barlier A, Morlet-Barlat N, et al. Should routine analysis of the MEN1 gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg 2010; 34:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/36\">",
"      Turner JJ, Christie PT, Pearce SH, et al. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Hum Mutat 2010; 31:E1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43240/abstract/37\">",
"      Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 2009; 33:1208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2039 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43240=[""].join("\n");
var outline_f42_14_43240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28380297\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF MEN1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4058708\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Parathyroid adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pancreatic islet cell/gastrointestinal adenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Zollinger-Ellison syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nonfunctioning pancreatic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cutaneous tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4058938\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DNA TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14907247\">",
"      Confirming the diagnosis of MEN1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24809205\">",
"      Screening of family members in MEN1 kindreds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14907078\">",
"      SCREENING FOR MEN1-ASSOCIATED TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28380297\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2039|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/25/404\" title=\"diagnostic image 1\">",
"      Zollinger Ellison syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2039|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/40/20108\" title=\"table 1\">",
"      MEN syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/56/37772\" title=\"table 2\">",
"      Expressions of MEN1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/5/3164\" title=\"table 3\">",
"      MEN1 vs RET tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5545?source=related_link\">",
"      Diagnosis and differential diagnosis of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_14_43241="Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses";
var content_f42_14_43241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43241/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43241/contributors\">",
"     John J Treanor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43241/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/14/43241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/14/43241/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/14/43241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gastroenteritis is one of the most common illnesses, affecting both adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/1\">",
"     1",
"    </a>",
"    ]. Infectious causes include viral, bacterial and protozoan organisms; in developed countries, the majority are due to viruses. Several groups of viruses are responsible for these infections, including the rotaviruses, enteric adenoviruses, astroviruses, and the human caliciviruses (including the noroviruses and sapoviruses). The caliciviruses are probably the most important cause of gastroenteritis in adults and older children, estimated to cause 23 million illnesses in the United States each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/2\">",
"     2",
"    </a>",
"    ]. In the United States, norovirus may be the etiologic agent in up to 7 percent of patients hospitalized for acute gastroenteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical characteristics of illness induced by the human caliciviruses and the astroviruses, as well as methods for their detection in stool samples will be reviewed here. Issues related to the more detailed epidemiology and prevention of norovirus infection and the clinical presentation of rotavirus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6313?source=see_link\">",
"     \"Epidemiology of viral gastroenteritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/48/26376?source=see_link\">",
"     \"Clinical presentation and diagnosis of rotavirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE AND VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calicivirus family includes pathogens of both human and animals. The human caliciviruses that cause acute gastroenteritis are divided into two genera, the Noroviruses (NoV) and the Sapoviruses (SaV). Noroviruses were first identified as viral causes of gastroenteritis in an outbreak in Norwalk, Ohio, and were previously referred to as the Norwalk-like viruses, or NLV. Similarly, the human caliciviruses that were first identified in Japan were referred to as the Sapporo agent; they are now classified as Sapoviruses.",
"   </p>",
"   <p>",
"    Caliciviruses contain a single-stranded RNA genome and have a relatively simple structure, containing one major (VP1) and one minor (VP2) capsid protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/4\">",
"     4",
"    </a>",
"    ]. Expression of the VP1 in experimental systems leads to formation of empty capsids or virus-like particles (VLPs) that are useful tools to generate immune reagents and investigate pathogenesis. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is a significant degree of genetic diversity among these viruses, particularly among the noroviruses, which are further subdivided into five genogroups based on sequence homology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/5\">",
"     5",
"    </a>",
"    ]. Genogroups GI, GII, and GIV include human pathogens and multiple genotypes are recognized within each genogroup. For example, there are currently at least eight distinct genotypes within genogroup GI and 27 genotypes within G2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/6\">",
"     6",
"    </a>",
"    ]. Frequent recombination between strains also contributes to genetic diversity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sapoviruses are also caliciviruses, and are differentiated from the norovirus on the basis of antigenic differences and differences in genome organizations. Sapoviruses are currently divided into five genogroups, GI-GV, with GI, GII, GIV, and GV associated with human infections and GIII found in porcine species. Like the noroviruses, frequent recombination contributes to the genetic diversity of these viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Astrovirus serotypes can be distinguished by immunofluorescence or plaque neutralization techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], while considerable cross-reactivity occurs with testing by enzyme immunoassay due to the presence of a group antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/12\">",
"     12",
"    </a>",
"    ]. At least eight serotypes of human astroviruses have been recognized (HastV-1 to HAstV-8), which have worldwide distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States between 2001 and 2009, the estimated annual mean rates of norovirus-associated visits to emergency departments and ambulatory clinics were 14 and 57 cases per 10,000 persons, respectively, across all ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/16\">",
"     16",
"    </a>",
"    ]. Norovirus was estimated to cause 13 percent of all gastroenteritis-associated visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4305303\">",
"    <span class=\"h2\">",
"     Norovirus",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4304369\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Norovirus can be transmitted easily person-to-person (via the fecal-oral route) and spread through airborne droplets, food, water, contaminated environmental surfaces, and fomites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noroviruses appear to be readily transmissible at relatively low doses, with an estimated median infectious dose of 18 viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/20\">",
"     20",
"    </a>",
"    ], and viral shedding can occur at extremely high levels of up to 7.7 x 10(10)",
"    <span class=\"nowrap\">",
"     viruses/gm",
"    </span>",
"    of stool and persist for weeks after symptoms have resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Viral shedding has been documented in vomitus and stool, although it is unclear if detection of virus indicates transmission risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the major route of transmission is fecal-oral, there are also observations from outbreaks that suggest that on occasion airborne transmission can occur, possibly when virus is aerosolized during vigorous emesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one outbreak, 364 restaurant patrons developed gastroenteritis after dining at a restaurant where employees had reported to work while ill [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/25\">",
"       25",
"      </a>",
"      ]. Attack rates increased after an episode of vomiting by one of the line cooks suggesting possible airborne spread from the kitchen to the main dining area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a recurring norovirus outbreak in a long-term residential treatment center, facility employees who cleaned up vomitus were at higher risk for illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/26\">",
"       26",
"      </a>",
"      ]. Gloves were worn by 97 percent of employees, but they rarely wore gowns or masks while cleaning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contamination of environmental surfaces may also play a role in prolonged outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most transmission probably occurs at the time when the patient is most symptomatic, there is also evidence of both presymptomatic and postsymptomatic transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4304385\">",
"    <span class=\"h3\">",
"     Outbreaks",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4308272\">",
"    <span class=\"h4\">",
"     Emergence of novel strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most epidemics of norovirus infection globally have been associated with the emergence of novel genotype II.4 strains; these viruses have been associated with higher hospitalization and death rates than other norovirus genotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/28-32\">",
"     28-32",
"    </a>",
"    ]. Two GII.4 variants were responsible for outbreaks of gastroenteritis in Australia and New Zealand in 2005 to 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/33\">",
"     33",
"    </a>",
"    ]. Subsequently, one of these strains was also linked to approximately one-fourth of the outbreaks reported in the United Kingdom. In 2012, GII.4 Sydney strain (named for the place in Australia where it was first isolated) replaced GII.4 New Orleans as the predominant strain in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/34\">",
"     34",
"    </a>",
"    ]. The proportion of outbreaks attributed to this new strain increased from 19 to 58 percent between September and December 2012.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Secondary attack rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks are characterized by high secondary attack rates. Consequently, these outbreaks have been reported in diverse settings, including nursing homes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/17,35\">",
"     17,35",
"    </a>",
"    ], long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/17\">",
"     17",
"    </a>",
"    ], retirement centers, and hospitals, as well as cruise ships, airplanes, schools, and day care centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Noroviruses have also been responsible for large outbreaks among disaster refugees such as after hurricane Katrina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/40\">",
"     40",
"    </a>",
"    ], and in military personnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/41\">",
"     41",
"    </a>",
"    ] and athletic teams.",
"   </p>",
"   <p>",
"    These outbreaks have been associated with significant morbidity among patients and healthcare workers and can lead to disruption of patient care. As an example, in a two-month outbreak at a United States-based tertiary care hospital, 90 patients and 265 healthcare workers were affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/38\">",
"     38",
"    </a>",
"    ]. Aggressive infection control measures, including closure of units and disinfection procedures, led to an estimated cost of more than $650,000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Food-borne outbreaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noroviruses are an important cause of food-borne outbreaks of gastroenteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/42\">",
"     42",
"    </a>",
"    ]. Shellfish are extremely common vehicles in such outbreaks. This is particularly true of oysters since they are filter feeders that concentrate on particulate matter from the environment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noroviruses are also frequent causes of travelers' diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Dual infections with enterotoxigenic E. coli are common in this setting. Noroviruses are being increasingly recognized as causes of sporadic gastroenteritis not associated with outbreaks as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noroviruses are increasingly recognized as an important cause of chronic gastroenteritis in immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/47\">",
"     47",
"    </a>",
"    ]. In a case series of 12 patients, norovirus was also described as a cause of persistent diarrhea and weight loss among adult allogeneic hematopoietic stem cell transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/48\">",
"     48",
"    </a>",
"    ]. In 10 patients, diarrhea persisted for a median of three months and was associated with high levels of viral shedding in stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Astrovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Astroviruses have also been associated with outbreaks of gastroenteritis, predominantly in children, such as in schools, day care settings, and pediatric wards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/49-54\">",
"     49-54",
"    </a>",
"    ]. Astroviruses have also been detected in the stools of immunosuppressed patients with diarrhea, including HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/55\">",
"     55",
"    </a>",
"    ] following bone marrow transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/56\">",
"     56",
"    </a>",
"    ], and in children with hematologic malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/57\">",
"     57",
"    </a>",
"    ]. However, the severity of illness in HIV-infected children with astrovirus is no greater than that seen in other children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Limited challenge studies in adults have suggested that the incubation period of astrovirus infection may be slightly longer, from three to four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sapovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sapovirus infections are associated with sporadic gastroenteritis in young children. Strains of sapoviruses have also been identified in clams from supermarkets and fish markets in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/62\">",
"     62",
"    </a>",
"    ]. No direct link has been demonstrated between ingestion of clams and gastroenteritis in this geographic region; however, this may be related to the local practice of boiling clams before consumption in soup dishes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the lack of animal models for gastroenteritis induced by the Norwalk viruses, information about the pathogenesis of this illness is based largely upon studies of experimentally induced disease in normal volunteers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infection with noroviruses produces a similar, reversible histopathologic lesion in the jejunum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/63-66\">",
"     63-66",
"    </a>",
"    ], with apparent sparing of the stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/67\">",
"     67",
"    </a>",
"    ] and rectum. The villi are blunted, but the mucosa is otherwise intact. Mononuclear and polymorphonuclear leukocytic infiltrations are seen in the lamina propria. On electron microscopy, the epithelial cells are intact, microvilli are shortened, and the intercellular spaces are widened.",
"   </p>",
"   <p>",
"    These histopathologic changes appear within 24 hours after virus challenge (whether symptomatic or subclinical), are present at the peak of illness, and persist for a variable period of time after the illness. They generally clear within two weeks after the onset of illness, although some jejunal changes have been noted as late as six weeks after challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intestinal physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea induced by norovirus is associated with transient malabsorption of D-xylose and fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/68\">",
"     68",
"    </a>",
"    ] and with decreased activity of brush-border enzymes including alkaline phosphatase and trehalase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/64\">",
"     64",
"    </a>",
"    ]. Absorption and brush-border enzyme levels return to normal values within two weeks after challenge.",
"   </p>",
"   <p>",
"    During acute illness, a variable amount of intestinal fluid is produced. However, infections with noroviruses have not been associated with detectable enterotoxin production and adenylate cyclase levels in jejunal biopsy specimens are normal during infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/69\">",
"     69",
"    </a>",
"    ]. Thus, the precise mechanisms of the viral-induced diarrhea remain unknown.",
"   </p>",
"   <p>",
"    The mechanisms by which these viruses induce vomiting are also unclear. Gastric emptying is markedly delayed in normal adults challenged with these viruses, but the degree of delay is not correlated with the severity of vomiting; in addition, there is no change in the basal or betazole-stimulated secretion of hydrochloric acid, pepsin, or intrinsic factor in subjects with illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known regarding the pathogenesis of illness associated with other human caliciviruses. Calicivirus infections in animals have been associated with atrophy of the small intestinal mucosa along with a mild inflammatory infiltrate in the lamina propria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of astrovirus-induced illness is not well understood. Astrovirus infections in animals are associated with small intestinal villus shortening and with mild inflammatory infiltrates in the lamina propria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/71,73\">",
"     71,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Host susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The noroviruses bind to several blood group antigens, which are complex carbohydrate structures expressed on a variety of cells including gastrointestinal epithelial cells. The specific antigens recognized vary by genogroup, with genogroup GI noroviruses preferentially binding to blood group antigens of A and O secretors, and genogroup GII viruses binding predominantly to A and B secretors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/74\">",
"     74",
"    </a>",
"    ]. The binding domain for these antigens has been localized to a pocket within the P2 domain of the viral capsid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These blood group antigens may serve either as receptors for the noroviruses or some other function that is critical for viral infection, because blood group is closely linked to susceptibility to norovirus genogroup 1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Specifically, nonsecretors appear to be quite resistant to infection even when exposed to large amounts of Norwalk virus. Individuals of blood type B also are somewhat resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/76,78\">",
"     76,78",
"    </a>",
"    ]. These findings may represent an explanation for observations of a poorly defined long-term resistance to infection seen in previous studies, in which some individuals consistently remained well, despite repeated challenge with virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a study of two separate outbreaks of gastroenteritis in Israeli military recruits, an association between genogroup II norovirus infection and ABO histo-blood group was not demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/80\">",
"     80",
"    </a>",
"    ]. These data support the hypothesis that genogroup II viruses are capable of infecting all secretors, regardless of ABO type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/74,80\">",
"     74,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Viral shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Norovirus shedding in stools, as detected by immune electron microscopy, is maximal over the first 24 to 48 hours after illness and is rarely detected beyond 72 hours after the onset of vomiting or diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. However, more prolonged shedding of virus after challenge has been detected by sensitive ELISA techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/83\">",
"     83",
"    </a>",
"    ] using hyperimmune animal sera and by reverse-transcriptase polymerase chain reaction (RT-PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/46\">",
"     46",
"    </a>",
"    ]. In a two-year survey in an acute care hospital, 8 (8.4 percent) of all norovirus positive patients demonstrated prolonged illness and viral shedding (duration, 21-182 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/84\">",
"     84",
"    </a>",
"    ]. All eight patients had underlying illnesses; five were immunocompromised hosts.",
"   </p>",
"   <p>",
"    The clinical significance of prolonged detection of antigen in stools in unclear, but epidemiologic data have implicated previously symptomatic individuals in transmission of virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/85\">",
"     85",
"    </a>",
"    ]. It has also been reported that the levels of viral shedding in genogroup GII infections is higher than that with genogroup GI, perhaps explaining their apparent higher transmissibility and prevalence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with noroviruses, sapoviruses or the astroviruses tends to produce a spectrum of illness ranging from mild febrile illness with watery diarrhea to more severe febrile illness with vomiting, headache, and constitutional symptoms. Vomiting is more prominent with the noroviruses than with astroviruses while the presentation of norovirus and sapovirus infections appears similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Norovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the clinical characteristics of illness due to the noroviruses has been obtained from naturally occurring cases and from volunteers who were experimentally infected with noroviruses of various genogroups. Despite differences in genetic sequence and receptor binding characteristics of these diverse viruses, the illness caused by each of the genogroup viruses appears clinically indistinguishable.",
"   </p>",
"   <p>",
"    Norovirus infection is associated with a spectrum of clinical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. The incubation period is generally 24 to 48 hours, with a range from 18 to 72 hours, and the onset of symptoms is typically abrupt. Most patients develop both vomiting and diarrhea, although either can be present alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, systemic manifestations, such as generalized myalgias, malaise, and headache are prominent. Fever (38.3 to 38.9&ordm;C [101 to 102&ordm;F]) occurs in approximately one-half of cases. Although patients are often uncomfortable, they usually do not appear severely ill, and disease manifestations generally last 48 to 72 hours with a full and rapid recovery.",
"   </p>",
"   <p>",
"    If diarrhea is present, it is generally moderate in amount, with four to eight stools being produced over a period of 24 hours. Gastroenteritis due to noroviruses is typically a noninflammatory small bowel infection. The stools are characteristically nonbloody, lack mucous, and may be loose to watery; fecal leukocytes are not seen.",
"   </p>",
"   <p>",
"    More severe manifestations of disease have been reported in young children under the age of one, elderly patients, and patients with underlying disease who acquire infection during nosocomial outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. In such individuals, fever is more common, and the disease may last several days longer than seen in healthy adults. There is limited experience with norovirus infections in immunocompromised individuals. The viruses may be shed for prolonged periods of time in persons with severe compromise of cellular immunity.",
"   </p>",
"   <p>",
"    Other laboratory tests generally remain normal. The peripheral white blood cell count is unchanged or slightly elevated, and relative lymphopenia may be observed at the height of the illness. Unless dehydration supervenes, the BUN and serum creatinine concentration do not change.",
"   </p>",
"   <p>",
"    The risk of dyspepsia, constipation, and reflux may be increased among patients who have acute gastroenteritis in the setting of a norovirus outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/91\">",
"     91",
"    </a>",
"    ]. Further investigation of postinfectious sequelae is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Sapovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sapovirus infections generally have similar presentations, although they have been less extensively studied. In one prospective study, sapovirus infections were restricted to children, as compared to noroviruses, which occurred in all age groups. In children, infection with either virus has a very similar clinical presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/46,92,93\">",
"     46,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although sapoviruses can occur in outbreaks, they are not characterized by the same high secondary attack rates, and the incubation period has not been well defined. The incubation period for astrovirus may be slightly longer than norovirus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Astrovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illness attributed to astroviruses is seen predominantly in children, and consists primarily of low-grade fever, diarrhea, headache, malaise, and nausea, whereas vomiting is less common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/53,94,95\">",
"     53,94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incubation period has been estimated to be approximately three to four days. Symptoms generally last two to three days, but can persist for a longer period. Stool filtrates that contain astroviruses readily infect volunteers after oral administration; however, they do not usually produce symptoms, which suggests that astroviruses may be less \"pathogenic\" in adults than are the Norwalk viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the usually characteristic clinical syndrome and the transient nature of the illness, specific viral diagnosis is usually not required in the management of acute viral gastroenteritis, particularly in adults. However, determination of the specific etiology of a particular outbreak can be useful in terminating and preventing future outbreaks. Amplification of genome from stool samples by reverse-transcriptase polymerase chain reaction (RT-PCR), or other nucleic acid based tests, is the mainstay of diagnosis. In addition, the use of virus-like particles (VLPs) to generate hyperimmune reagents has provided the basis for development of a variety of antigen detection enzyme immunoassays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noroviruses were initially identified by electron microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/96\">",
"     96",
"    </a>",
"    ]. Diagnosis of these infections relied heavily on identification of their characteristic morphology, aided by the addition of postinfection sera, a technique referred to as immune electron microscopy. While this technique may be useful for the detection of new agents, it is relatively insensitive for diagnosis of norovirus infection, in which the numbers of intact virion particles present in diarrheal stools appear to be low. In contrast to the noroviruses, astroviruses are often shed in large amounts in stool and can be readily detected by electron microscopy even without immune aggregation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noroviruses and sapoviruses are readily detected using RT-PCR based testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/97-100\">",
"     97-100",
"    </a>",
"    ], and this approach is currently the mainstay of diagnosis.",
"   </p>",
"   <p>",
"    The detection of noroviruses in fecal specimens by RT-PCR may be limited by factors such as low virus concentrations in feces, improper specimen storage, inefficient viral RNA extraction, and presence of fecal reverse transcriptase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/101\">",
"     101",
"    </a>",
"    ]. Conversely, carefully selected primers within relatively more divergent capsid regions can be used to differentiate virus strains genotypically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCR techniques are also used widely for the detection of virus in food and environmental samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. Nucleic acid hybridization and PCR-based detection techniques have also been reported for the astroviruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/76,78\">",
"     76,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Immunoassay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of viral antigen by immunoassay does not require the presence of morphologically intact virions, and can therefore be considerably more sensitive than electron microscopic techniques. Immunoassays have been developed using sera generated against VLPs or monoclonal antibodies, and several are commercially available. Although these assays are technically simpler to perform than RT-PCR, they are generally less sensitive and specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/107-111\">",
"     107-111",
"    </a>",
"    ]. Thus, these assays have limited utility in the diagnosis of sporadic cases of gastroenteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/108\">",
"     108",
"    </a>",
"    ], but are useful in outbreak scenarios where multiple samples are available for testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enzyme immunoassay techniques that detect the astrovirus group antigen have also been widely used in epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cell culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propagation of these viruses in cell culture is difficult and not used for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there are multiple potential routes for transmission of norovirus, including environmental surfaces, airborne, and person-to-person contact, it is sometimes difficult to quickly contain an outbreak.",
"   </p>",
"   <p>",
"    To reduce the risk for norovirus transmission through aerosolized vomitus, public health departments recommend the following steps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove vomitus and fecal material carefully to limit aerosolization (ie, soaking up material with disposable cloths or towels with minimal agitation with disposal in impervious bags).",
"     </li>",
"     <li>",
"      Thoroughly clean surfaces and disinfect with 5000 ppm hypochlorite solution",
"     </li>",
"     <li>",
"      Wear personal protective equipment when cleaning vomitus or feces (ie, gloves, masks, and gowns).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4306092\">",
"    <span class=\"h2\">",
"     Epidemiologic investigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic investigations assess the likelihood of norovirus in outbreak situations with specific clinical and laboratory criteria including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/115\">",
"     115",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An average incubation period from 24 to 48 hours",
"     </li>",
"     <li>",
"      An average duration of illness of 12 to 60 hours",
"     </li>",
"     <li>",
"      Vomiting reported in more than half of cases",
"     </li>",
"     <li>",
"      Negative stool cultures for bacterial pathogens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies using modern diagnostic techniques have confirmed the accuracy of these criteria in assessing the likelihood of norovirus involvement in clustering of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/116\">",
"     116",
"    </a>",
"    ]. In one study, norovirus infection was identified by reverse transcriptase polymerase chain reaction (RT-PCR) testing as the causative agent in 184 of 226 (81 percent) of outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/36\">",
"     36",
"    </a>",
"    ]. Another study has suggested that norovirus genotype profiles may enhance detection of the source of foodborne outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/14/43241/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/3/9267?source=see_link\">",
"       \"Patient information: Viral gastroenteritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The caliciviruses (including noroviruses and sapoviruses) and the astroviruses are important etiologic agents of gastroenteritis in adults and older children in the United States and worldwide. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noroviruses are infectious at relatively low doses and outbreaks are characterized by high secondary attack rates. The incubation period is short (approximately 48 hours). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although sapoviruses and astroviruses can also occur in outbreaks, they are not characterized by the same high secondary attack rates, and the incubation period has not been well defined. The incubation period for astrovirus may be slightly longer than norovirus. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The noroviruses bind to several blood group antigens, which are complex carbohydrate structures expressed on a variety of cells including gastrointestinal epithelial cells. The specific antigens recognized vary by genogroup. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of symptoms with norovirus is typically abrupt and often includes vomiting and diarrhea; fever is present in approximately half of patients. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Illness attributed to astroviruses is seen predominantly in children, and consists primarily of low-grade fever, diarrhea, headache, malaise, and nausea, whereas vomiting is less common. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/1\">",
"      Bresee JS, Widdowson MA, Monroe SS, Glass RI. Foodborne viral gastroenteritis: challenges and opportunities. Clin Infect Dis 2002; 35:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/2\">",
"      Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/3\">",
"      Lopman BA, Hall AJ, Curns AT, Parashar UD. Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996-2007. Clin Infect Dis 2011; 52:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/4\">",
"      Lambden PR, Caul EO, Ashley CR, Clarke IN. Sequence and genome organization of a human small round-structured (Norwalk-like) virus. Science 1993; 259:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/5\">",
"      Hutson AM, Atmar RL, Estes MK. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol 2004; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/6\">",
"      Zheng DP, Ando T, Fankhauser RL, et al. Norovirus classification and proposed strain nomenclature. Virology 2006; 346:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/7\">",
"      Etherington GJ, Dicks J, Roberts IN. High throughput sequence analysis reveals hitherto unreported recombination in the genus Norovirus. Virology 2006; 345:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/8\">",
"      Ambert-Balay K, Bon F, Le Guyader F, et al. Characterization of new recombinant noroviruses. J Clin Microbiol 2005; 43:5179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/9\">",
"      Hansman GS, Oka T, Katayama K, Takeda N. Human sapoviruses: genetic diversity, recombination, and classification. Rev Med Virol 2007; 17:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/10\">",
"      Kurtz JB, Lee TW. Human astrovirus serotypes. Lancet 1984; 2:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/11\">",
"      Hudson RW, Herrmann JE, Blacklow NR. Plaque quantitation and virus neutralization assays for human astroviruses. Arch Virol 1989; 108:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/12\">",
"      Herrmann JE, Hudson RW, Perron-Henry DM, et al. Antigenic characterization of cell-cultivated astrovirus serotypes and development of astrovirus-specific monoclonal antibodies. J Infect Dis 1988; 158:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/13\">",
"      Lee TW, Kurtz JB. Prevalence of human astrovirus serotypes in the Oxford region 1976-92, with evidence for two new serotypes. Epidemiol Infect 1994; 112:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/14\">",
"      Noel JS, Lee TW, Kurtz JB, et al. Typing of human astroviruses from clinical isolates by enzyme immunoassay and nucleotide sequencing. J Clin Microbiol 1995; 33:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/15\">",
"      Taylor MB, Walter J, Berke T, et al. Characterisation of a South African human astrovirus as type 8 by antigenic and genetic analyses. J Med Virol 2001; 64:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/16\">",
"      Gasta&ntilde;aduy PA, Hall AJ, Curns AT, et al. Burden of norovirus gastroenteritis in the ambulatory setting--United States, 2001-2009. J Infect Dis 2013; 207:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/17\">",
"      Said MA, Perl TM, Sears CL. Healthcare epidemiology: gastrointestinal flu: norovirus in health care and long-term care facilities. Clin Infect Dis 2008; 47:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/18\">",
"      Parashar U, Quiroz ES, Mounts AW, et al. \"Norwalk-like viruses\". Public health consequences and outbreak management. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/19\">",
"      Repp KK, Keene WE. A point-source norovirus outbreak caused by exposure to fomites. J Infect Dis 2012; 205:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/20\">",
"      Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it? J Med Virol 2008; 80:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/21\">",
"      Chan MC, Sung JJ, Lam RK, et al. Fecal viral load and norovirus-associated gastroenteritis. Emerg Infect Dis 2006; 12:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/22\">",
"      Moe CL. Preventing norovirus transmission: how should we handle food handlers? Clin Infect Dis 2009; 48:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/23\">",
"      Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Updated norovirus outbreak management and disease prevention guidelines. MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/24\">",
"      Marks PJ, Vipond IB, Regan FM, et al. A school outbreak of Norwalk-like virus: evidence for airborne transmission. Epidemiol Infect 2003; 131:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Norovirus outbreak associated with ill food-service workers--Michigan, January-February 2006. MMWR Morb Mortal Wkly Rep 2007; 56:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Recurring norovirus outbreaks in a long-term residential treatment facility - Oregon, 2007. MMWR Morb Mortal Wkly Rep 2009; 58:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/27\">",
"      Wu HM, Fornek M, Schwab KJ, et al. A norovirus outbreak at a long-term-care facility: the role of environmental surface contamination. Infect Control Hosp Epidemiol 2005; 26:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/28\">",
"      Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis 2009; 200:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/29\">",
"      Desai R, Hembree CD, Handel A, et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. Clin Infect Dis 2012; 55:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/30\">",
"      Widdowson MA, Cramer EH, Hadley L, et al. Outbreaks of acute gastroenteritis on cruise ships and on land: identification of a predominant circulating strain of norovirus--United States, 2002. J Infect Dis 2004; 190:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/31\">",
"      Lopman B, Vennema H, Kohli E, et al. Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. Lancet 2004; 363:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Norovirus activity--United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/33\">",
"      Tu ET, Bull RA, Greening GE, et al. Epidemics of gastroenteritis during 2006 were associated with the spread of norovirus GII.4 variants 2006a and 2006b. Clin Infect Dis 2008; 46:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Emergence of new norovirus strain GII.4 Sydney--United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/35\">",
"      Trivedi TK, DeSalvo T, Lee L, et al. Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009-2010. JAMA 2012; 308:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/36\">",
"      Blanton LH, Adams SM, Beard RS, et al. Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000-2004. J Infect Dis 2006; 193:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/37\">",
"      Fankhauser RL, Monroe SS, Noel JS, et al. Epidemiologic and molecular trends of \"Norwalk-like viruses\" associated with outbreaks of gastroenteritis in the United States. J Infect Dis 2002; 186:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/38\">",
"      Johnston CP, Qiu H, Ticehurst JR, et al. Outbreak management and implications of a nosocomial norovirus outbreak. Clin Infect Dis 2007; 45:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/39\">",
"      Kirking HL, Cortes J, Burrer S, et al. Likely transmission of norovirus on an airplane, October 2008. Clin Infect Dis 2010; 50:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/40\">",
"      Yee EL, Palacio H, Atmar RL, et al. Widespread outbreak of norovirus gastroenteritis among evacuees of Hurricane Katrina residing in a large \"megashelter\" in Houston, Texas: lessons learned for prevention. Clin Infect Dis 2007; 44:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/41\">",
"      Thornton SA, Sherman SS, Farkas T, et al. Gastroenteritis in US Marines during Operation Iraqi Freedom. Clin Infect Dis 2005; 40:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/42\">",
"      Malek M, Barzilay E, Kramer A, et al. Outbreak of norovirus infection among river rafters associated with packaged delicatessen meat, Grand Canyon, 2005. Clin Infect Dis 2009; 48:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: norovirus infections associated with frozen raw oysters - Washington, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/44\">",
"      Ko G, Garcia C, Jiang ZD, et al. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol 2005; 43:6126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/45\">",
"      Chapin AR, Carpenter CM, Dudley WC, et al. Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrhea. J Clin Microbiol 2005; 43:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/46\">",
"      Rockx B, De Wit M, Vennema H, et al. Natural history of human calicivirus infection: a prospective cohort study. Clin Infect Dis 2002; 35:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/47\">",
"      Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 2012; 367:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/48\">",
"      Roddie C, Paul JP, Benjamin R, et al. Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity. Clin Infect Dis 2009; 49:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/49\">",
"      Madeley CR, Cosgrove BP. Letter: 28 nm particles in faeces in infantile gastroenteritis. Lancet 1975; 2:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/50\">",
"      Ashley CR, Caul EO, Paver WK. Astrovirus-associated gastroenteritis in children. J Clin Pathol 1978; 31:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/51\">",
"      Kurtz JB, Lee TW, Pickering D. Astrovirus associated gastroenteritis in a children's ward. J Clin Pathol 1977; 30:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/52\">",
"      Konno T, Suzuki H, Ishida N, et al. Astrovirus-associated epidemic gastroenteritis in Japan. J Med Virol 1982; 9:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/53\">",
"      Lew JF, Moe CL, Monroe SS, et al. Astrovirus and adenovirus associated with diarrhea in children in day care settings. J Infect Dis 1991; 164:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/54\">",
"      Esahli H, Breb&auml;ck K, Bennet R, et al. Astroviruses as a cause of nosocomial outbreaks of infant diarrhea. Pediatr Infect Dis J 1991; 10:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/55\">",
"      Grohmann GS, Glass RI, Pereira HG, et al. Enteric viruses and diarrhea in HIV-infected patients. Enteric Opportunistic Infections Working Group. N Engl J Med 1993; 329:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/56\">",
"      Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994; 107:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/57\">",
"      Coppo P, Scieux C, Ferchal F, et al. Astrovirus enteritis in a chronic lymphocytic leukemia patient treated with fludarabine monophosphate. Ann Hematol 2000; 79:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/58\">",
"      Liste MB, Natera I, Suarez JA, et al. Enteric virus infections and diarrhea in healthy and human immunodeficiency virus-infected children. J Clin Microbiol 2000; 38:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/59\">",
"      Giordano MO, Martinez LC, Rinaldi D, et al. Diarrhea and enteric emerging viruses in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/60\">",
"      Kurtz JB, Lee TW, Craig JW, Reed SE. Astrovirus infection in volunteers. J Med Virol 1979; 3:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/61\">",
"      Midthun K, Greenberg HB, Kurtz JB, et al. Characterization and seroepidemiology of a type 5 astrovirus associated with an outbreak of gastroenteritis in Marin County, California. J Clin Microbiol 1993; 31:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/62\">",
"      Hansman GS, Oka T, Okamoto R, et al. Human sapovirus in clams, Japan. Emerg Infect Dis 2007; 13:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/63\">",
"      Dolin R, Levy AG, Wyatt RG, et al. Viral gastroenteritis induced by the Hawaii agent. Jejunal histopathology and serologic response. Am J Med 1975; 59:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/64\">",
"      Agus SG, Dolin R, Wyatt RG, et al. Acute infectious nonbacterial gastroenteritis: intestinal histopathology. Histologic and enzymatic alterations during illness produced by the Norwalk agent in man. Ann Intern Med 1973; 79:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/65\">",
"      Schreiber DS, Blacklow NR, Trier JS. The mucosal lesion of the proximal small intestine in acute infectious nonbacterial gastroenteritis. N Engl J Med 1973; 288:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/66\">",
"      Schreiber DS, Blacklow NR, Trier JS. The small intestinal lesion induced by Hawaii agent acute infectious nonbacterial gastroenteritis. J Infect Dis 1974; 129:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/67\">",
"      Widerlite L, Trier JS, Blacklow NR, Schreiber DS. Structure of the gastric mucosa in acute infectious bacterial gastroenteritis. Gastroenterology 1975; 68:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/68\">",
"      Acute infectious nonbacterial gastroenteritis: etiology and pathogenesis. Ann Intern Med 1972; 76:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/69\">",
"      Levy AG, Widerlite L, Schwartz CJ, et al. Jejunal adenylate cyclase activity in human subjects during viral gastroenteritis. Gastroenterology 1976; 70:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/70\">",
"      Meeroff JC, Schreiber DS, Trier JS, Blacklow NR. Abnormal gastric motor function in viral gastroenteritis. Ann Intern Med 1980; 92:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/71\">",
"      Woode GN, Bridger JC. Isolation of small viruses resembling astroviruses and caliciviruses from acute enteritis of calves. J Med Microbiol 1978; 11:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/72\">",
"      Saif LJ, Bohl EH, Theil KW, et al. Rotavirus-like, calicivirus-like, and 23-nm virus-like particles associated with diarrhea in young pigs. J Clin Microbiol 1980; 12:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/73\">",
"      Snodgrass DR, Angus KW, Gray EW, et al. Pathogenesis of diarrhoea caused by astrovirus infections in lambs. Arch Virol 1979; 60:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/74\">",
"      Huang P, Farkas T, Marionneau S, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003; 188:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/75\">",
"      Tan M, Huang P, Meller J, et al. Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J Virol 2003; 77:12562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/76\">",
"      Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002; 185:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/77\">",
"      Rockx BH, Vennema H, Hoebe CJ, et al. Association of histo-blood group antigens and susceptibility to norovirus infections. J Infect Dis 2005; 191:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/78\">",
"      Lindesmith L, Moe C, Marionneau S, et al. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/79\">",
"      Parrino TA, Schreiber DS, Trier JS, et al. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 1977; 297:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/80\">",
"      Halperin T, Vennema H, Koopmans M, et al. No association between histo-blood group antigens and susceptibility to clinical infections with genogroup II norovirus. J Infect Dis 2008; 197:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/81\">",
"      Dolin R, Reichman RC, Roessner KD, et al. Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis. J Infect Dis 1982; 146:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/82\">",
"      Thornhill TS, Kalica AR, Wyatt RG, et al. Pattern of shedding of the Norwalk particle in stools during experimentally induced gastroenteritis in volunteers as determined by immune electron microscopy. J Infect Dis 1975; 132:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/83\">",
"      Graham DY, Jiang X, Tanaka T, et al. Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis 1994; 170:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/84\">",
"      Siebenga JJ, Beersma MF, Vennema H, et al. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. J Infect Dis 2008; 198:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/85\">",
"      Patterson T, Hutchings P, Palmer S. Outbreak of SRSV gastroenteritis at an international conference traced to food handled by a post-symptomatic caterer. Epidemiol Infect 1993; 111:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/86\">",
"      Dolin R, Treanor JJ, Madore HP. Novel agents of viral enteritis in humans. J Infect Dis 1987; 155:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/87\">",
"      Estes MK, Prasad BV, Atmar RL. Noroviruses everywhere: has something changed? Curr Opin Infect Dis 2006; 19:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/88\">",
"      Goller JL, Dimitriadis A, Tan A, et al. Long-term features of norovirus gastroenteritis in the elderly. J Hosp Infect 2004; 58:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/89\">",
"      Lopman BA, Reacher MH, Vipond IB, et al. Clinical manifestation of norovirus gastroenteritis in health care settings. Clin Infect Dis 2004; 39:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/90\">",
"      Mattner F, Sohr D, Heim A, et al. Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect 2006; 12:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/91\">",
"      Porter CK, Faix DJ, Shiau D, et al. Postinfectious gastrointestinal disorders following norovirus outbreaks. Clin Infect Dis 2012; 55:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/92\">",
"      Vernacchio L, Vezina RM, Mitchell AA, et al. Diarrhea in American infants and young children in the community setting: incidence, clinical presentation and microbiology. Pediatr Infect Dis J 2006; 25:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/93\">",
"      Rosenfeldt V, Vesikari T, Pang XL, et al. Viral etiology and incidence of acute gastroenteritis in young children attending day-care centers. Pediatr Infect Dis J 2005; 24:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/94\">",
"      Moe CL, Allen JR, Monroe SS, et al. Detection of astrovirus in pediatric stool samples by immunoassay and RNA probe. J Clin Microbiol 1991; 29:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/95\">",
"      Glass RI, Noel J, Mitchell D, et al. The changing epidemiology of astrovirus-associated gastroenteritis: a review. Arch Virol Suppl 1996; 12:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/96\">",
"      Marshall JA, Bruggink LD. Laboratory diagnosis of norovirus. Clin Lab 2006; 52:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/97\">",
"      Jiang X, Wang J, Graham DY, Estes MK. Detection of Norwalk virus in stool by polymerase chain reaction. J Clin Microbiol 1992; 30:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/98\">",
"      Moe CL, Gentsch J, Ando T, et al. Application of PCR to detect Norwalk virus in fecal specimens from outbreaks of gastroenteritis. J Clin Microbiol 1994; 32:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/99\">",
"      Schwab KJ, Estes MK, Neill FH, Atmar RL. Use of heat release and an internal RNA standard control in reverse transcription-PCR detection of Norwalk virus from stool samples. J Clin Microbiol 1997; 35:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/100\">",
"      Ando T, Monroe SS, Noel JS, Glass RI. A one-tube method of reverse transcription-PCR to efficiently amplify a 3-kilobase region from the RNA polymerase gene to the poly(A) tail of small round-structured viruses (Norwalk-like viruses). J Clin Microbiol 1997; 35:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/101\">",
"      Patel MM, Widdowson MA, Glass RI, et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008; 14:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/102\">",
"      Ando T, Monroe SS, Gentsch JR, et al. Detection and differentiation of antigenically distinct small round-structured viruses (Norwalk-like viruses) by reverse transcription-PCR and southern hybridization. J Clin Microbiol 1995; 33:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/103\">",
"      Atmar RL, Neill FH, Romalde JL, et al. Detection of Norwalk virus and hepatitis A virus in shellfish tissues with the PCR. Appl Environ Microbiol 1995; 61:3014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/104\">",
"      Atmar RL, Neill FH, Woodley CM, et al. Collaborative evaluation of a method for the detection of Norwalk virus in shellfish tissues by PCR. Appl Environ Microbiol 1996; 62:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/105\">",
"      Atmar RL, Metcalf TG, Neill FH, Estes MK. Detection of enteric viruses in oysters by using the polymerase chain reaction. Appl Environ Microbiol 1993; 59:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/106\">",
"      Beuret C. Simultaneous detection of enteric viruses by multiplex real-time RT-PCR. J Virol Methods 2004; 115:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/107\">",
"      de Bruin E, Duizer E, Vennema H, Koopmans MP. Diagnosis of Norovirus outbreaks by commercial ELISA or RT-PCR. J Virol Methods 2006; 137:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/108\">",
"      Gonz&aacute;lez GG, Liprandi F, Ludert JE. Evaluation of a commercial enzyme immunoassay for the detection of norovirus antigen in fecal samples from children with sporadic acute gastroenteritis. J Virol Methods 2006; 136:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/109\">",
"      Burton-MacLeod JA, Kane EM, Beard RS, et al. Evaluation and comparison of two commercial enzyme-linked immunosorbent assay kits for detection of antigenically diverse human noroviruses in stool samples. J Clin Microbiol 2004; 42:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/110\">",
"      Vinj&eacute; J, Vennema H, Maunula L, et al. International collaborative study to compare reverse transcriptase PCR assays for detection and genotyping of noroviruses. J Clin Microbiol 2003; 41:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/111\">",
"      Richards AF, Lopman B, Gunn A, et al. Evaluation of a commercial ELISA for detecting Norwalk-like virus antigen in faeces. J Clin Virol 2003; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/112\">",
"      Dimitriadis A, Bruggink LD, Marshall JA. Evaluation of the Dako IDEIA norovirus EIA assay for detection of norovirus using faecal specimens from Australian gastroenteritis outbreaks. Pathology 2006; 38:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/113\">",
"      Dimitriadis A, Marshall JA. Evaluation of a commercial enzyme immunoassay for detection of norovirus in outbreak specimens. Eur J Clin Microbiol Infect Dis 2005; 24:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/114\">",
"      Herrmann JE, Nowak NA, Perron-Henry DM, et al. Diagnosis of astrovirus gastroenteritis by antigen detection with monoclonal antibodies. J Infect Dis 1990; 161:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/115\">",
"      Kaplan JE, Feldman R, Campbell DS, et al. The frequency of a Norwalk-like pattern of illness in outbreaks of acute gastroenteritis. Am J Public Health 1982; 72:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/116\">",
"      Turcios RM, Widdowson MA, Sulka AC, et al. Reevaluation of epidemiological criteria for identifying outbreaks of acute gastroenteritis due to norovirus: United States, 1998-2000. Clin Infect Dis 2006; 42:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/14/43241/abstract/117\">",
"      Verhoef L, Vennema H, van Pelt W, et al. Use of norovirus genotype profiles to differentiate origins of foodborne outbreaks. Emerg Infect Dis 2010; 16:617.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2710 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43241=[""].join("\n");
var outline_f42_14_43241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE AND VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4305303\">",
"      Norovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4304369\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4304385\">",
"      - Outbreaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4308272\">",
"      Emergence of novel strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary attack rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Food-borne outbreaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Astrovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sapovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intestinal physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Host susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Viral shedding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Norovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Sapovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Astrovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Immunoassay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cell culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4306092\">",
"      Epidemiologic investigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6313?source=related_link\">",
"      Epidemiology of viral gastroenteritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_14_43242="Androgenetic alopecia bitemporal recession";
var content_f42_14_43242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83802%7EDERM%2F83804%7EDERM%2F63010%7EDERM%2F83805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83802%7EDERM%2F83804%7EDERM%2F63010%7EDERM%2F83805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bitemporal hair loss in a man with androgenetic alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair loss on the vertex of the scalp in a man with androgenetic alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This man developed gradual thinning of hair on the vertex and frontoparietal areas of the scalp. Bitemporal recession is evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hair loss in androgenetic alopecia. Terminal hairs on the occipital scalp are spared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43242=[""].join("\n");
var outline_f42_14_43242=null;
var title_f42_14_43243="ASGE guidelines for warfarin";
var content_f42_14_43243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ASGE recommendations for adjusting warfarin prior to elective endoscopic procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low-risk procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No adjustments in anticoagulation need to be made irrespective of the underlying condition. However, elective procedures should be avoided when the level of anticoagulation is above the therapeutic range.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-risk procedures in patients with low-risk conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin therapy should be discontinued 3 to 5 days before the scheduled procedure. The decision to obtain a preprocedure prothrombin time should be individualized.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High-risk procedures in patients with high-risk conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin therapy should be discontinued 3 to 5 days before the procedure. The decision to administer intravenous heparin once the INR falls below the therapeutic level should be individualized. Preliminary experience suggest there may be a role for monitored reduction in the INR without the use of heparin. Heparin, if used, should be discontinued 4 to 6 hours before the scheduled procedure and may be resumed 2 to 6 hours after the procedure. Warfarin therapy may generally be resumed the night of the procedure. Heparin infusion and warfarin should overlap for a period of 4 to 5 days or until the INR has achieved the target therapeutic range for 2 to 3 days. However, the risk of major hemorrhage after sphincterotomy is between 10 and 15 percent if anticoagulation is reinstituted within three days of the sphincterotomy. Therefore, the benefits of immediate anticoagulation should be carefully weighed against the risks and would be advisable only in a situation where the risk of thromboembolic events significantly exceeds the risk of hemorrhage from sphincterotomy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eisen, GM, Baron, TH, Dominitz, JA, et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002; 55:775.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43243=[""].join("\n");
var outline_f42_14_43243=null;
var title_f42_14_43244="Percutaneous intervention for claudication guideline summary";
var content_f42_14_43244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percutaneous intervention for claudication guideline summary",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that endovascular treatment is beneficial in the following settings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; A patient with claudication that causes significant disability that limits lifestyle and/or work is not adequately responsive to exercise or pharmacologic therapy, has a reasonable likelihood of improvement, and is due to a lesion with a favorable risk-benefit ratio (eg, focal aortoiliac occlusive disease). Before intervention for 50 to 75 percent angiographic iliac artery stenoses, translesional pressure gradients should be obtained, with and without vasodilation, to determine the significance of the lesion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; TASC type A (single stenosis less than 3 cm) iliac and femoropopliteal arterial lesions for which endovascular treatment is the preferred revascularization technique.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Provisional stent placement in iliac arteries as salvage therapy for a suboptimal or failed result from balloon angioplasty alone (as manifested by a persistent translesional gradient, residual diameter stenosis of more than 50 percent, or a flow-limiting dissection).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Stenting as primary therapy for stenoses and occlusions of the common or external iliac artery.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The evidence or opinion is in favor of endovascular treatment being beneficial in the following setting",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Stents (and other adjunctive percutaneous techniques such as atherectomy and cutting balloons) in the femoral, popliteal, and tibial arteries as salvage therapy for a suboptimal or failed result from balloon angioplasty alone as defined above.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The evidence or opinion is less well established that endovascular treatment is beneficial in the following settings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Stents and other adjunctive percutaneous techniques for femoropopliteal arterial lesions, except as salvage therapy for a suboptimal result from balloon angioplasty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Uncoated/uncovered stents and other adjunctive percutaneous techniques infrapopliteal lesions, except as salvage therapy for a suboptimal result from balloon angioplasty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that endovascular treatment should not be performed in the following settings",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Absence of a significant pressure gradient across a stenosis despite flow augmentation with vasodilators.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Primary stent placement (ie, not for salvage therapy) in the femoral, popliteal, or tibial arteries.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; As prophylactic therapy in asymptomatic patients.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hirsch, AT, Haskal, ZJ, Hertzer, NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43244=[""].join("\n");
var outline_f42_14_43244=null;
var title_f42_14_43245="Causes of failure to thrive";
var content_f42_14_43245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of failure to thrive",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inadequate calorie intake",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Weight gain during refeeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inappropriate feeding technique",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Disturbed mother/child relationship*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inappropriate nutrient intake- eg, excess fruit juice consumption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Factitious food allergy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inadequate quantity of food",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inappropriate food for age",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neglect",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            No weight gain during refeeding",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psychosocial problems*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal/infant dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Economic deprivation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mechanical problems- adenoidal hypertrophy, dental lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Insufficient lactation in mother",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cleft palate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nasal obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sucking or swallowing dysfunction (CNS, neuromuscular, esophageal motility problems)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Regurgitation- gastroesophageal reflux",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malformation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Congenital syndromes- alcohol, pheytoin, drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Genetic syndromes- Turner",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Inadequate appetite or inability to eat large amounts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psychosocial problems- apathy*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cardiopulmonary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypotonia- muscle weakness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anorexia of chronic infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Immune deficiency diseases- HIV infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Endocrine disorders- hypothyroidism, diabetes insipidus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CNS tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Genetic syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Metabolic conditions- lead toxicity, iron or zinc deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic constipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Disturbance in appetite and satiety",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inadequate calorie absorption",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            No weight gain during refeeding; increased losses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psychosocial problems (refeeding diarrhea, intercurrent illnesses, rumination, regurgitation)*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malabsorption- diarrhea (lactose intolerance, cystic fibrosis, cardiac disease, malrotation, inflammatory bowel disease, milk allergy, parasites, celiac disease)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vomiting or \"spitting up\" or diarrhea (gastroenteritis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intestinal tract obstruction (pyloric stenosis, hernia, malrotation, intussusception, chalasia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Biliary atresia/cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            CNS problems- increased intracranial pressure (subdural hematoma)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Chronic metabolic problems (hypercalcemia, storage diseases, and inborn errors of metabolism such as galactosemia, methylmalonic acidemia, renal tubular acidosis, diabetes mellitus, adrenal insufficiency)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Increased calorie requirements",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebral palsy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malignancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic systemic disease (juvenile idiopathic arthritis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic systemic infection (UTI, tuberculosis, toxoplasmosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic respiratory insufficiency (bronchopulmonary dysplasia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital or acquired heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxins (lead)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Environmental causes are the most common source of problems.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43245=[""].join("\n");
var outline_f42_14_43245=null;
var title_f42_14_43246="Healthcare delivery mods";
var content_f42_14_43246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Models of healthcare delivery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from National Consensus Project for Quality Palliative Care (2004). Clinical practice guidelines for quality palliative care. file://www.nationalconsensusproject.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43246=[""].join("\n");
var outline_f42_14_43246=null;
var title_f42_14_43247="Generation of the QRS complex";
var content_f42_14_43247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Generation of the QRS complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ventricular depolarization can be divided into two major phases, each represented by a vector. Panel A: The first phase (arrow 1) denotes depolarization of the ventricular septum, beginning on the left side and spreading to the right. This process is represented by a small \"septal\" r wave in the anterior-posterior lead V1 and a small septal q wave in the left-right lead V6. Panel B: Simultaneous depolarization of the left and right ventricles (LV and RV) constitutes the second phase. This second vector (arrow 2) is oriented to the left and posteriorly, reflecting the electrical predominance of the LV. The net effect is an S wave in lead V1 and an R wave in lead V6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_14_43247=[""].join("\n");
var outline_f42_14_43247=null;
